

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Creation of an electronic patient-reported outcome measure platform Voxe: A protocol in pediatric solid organ transplantation

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-053119
Article Type:	Protocol
Date Submitted by the Author:	05-May-2021
Complete List of Authors:	<p>Anthony, Samantha; The Hospital for Sick Children, Child Health Evaluative Sciences; University of Toronto, Factor-Inwentash Faculty of Social Work</p> <p>Pol, Sarah; The Hospital for Sick Children, Child Health Evaluative Sciences</p> <p>Lin, Jia; The Hospital for Sick Children, Child Health Evaluative Sciences</p> <p>Barwick, Melanie; The Hospital for Sick Children, Child Health Evaluative Sciences; University of Toronto, Dalla Lana School of Public Health</p> <p>Brudno, Michael; University Health Network, Data Aggregation, Translation and Architecture; University of Toronto, Faculty of Arts and Science</p> <p>Manase, Dorin; University Health Network, Data Aggregation, Translation and Architecture</p> <p>Parekh, Rulan; The Hospital for Sick Children, Child Health Evaluative Sciences; The Hospital for Sick Children, Transplant and Regenerative Medicine Centre</p> <p>Silva, Amanda; University Health Network, Data Aggregation, Translation and Architecture</p> <p>Stinson, Jennifer; The Hospital for Sick Children, Child Health Evaluative Sciences; University of Toronto, Lawrence S. Bloomberg Faculty of Nursing</p>
Keywords:	Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Transplant medicine < INTERNAL MEDICINE, MENTAL HEALTH, PAEDIATRICS, Paediatric transplant surgery < PAEDIATRIC SURGERY, QUALITATIVE RESEARCH

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Title

Creation of an electronic patient-reported outcome measure platform Voxe: A protocol in pediatric solid organ transplantation

Authors

Samantha J. Anthony¹⁻⁴, Sarah J. Pol¹, Jia Lin¹, Melanie Barwick^{1,5,6}, Michael Brudno^{7,8}, Dorin Manase⁷, Rulan S. Parekh^{1,2,9,10}, Amanda Silva⁷, Jennifer Stinson^{1,11}

1. Child Health Evaluative Sciences, Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, Toronto, ON, Canada
2. Transplant and Regenerative Medicine Centre, The Hospital for Sick Children, Toronto, ON, Canada
3. Factor-Inwentash Faculty of Social Work, University of Toronto, Toronto, ON, Canada
4. Canadian Donation and Transplantation Research Program, Edmonton, AB, Canada
5. Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
6. Temerty Faculty of Medicine, Department of Psychiatry, University of Toronto, Toronto, ON, Canada
7. Data Aggregation, Translation and Architecture, University Health Network, Toronto, ON, Canada
8. Faculty of Arts and Science, Department of Computer Science, University of Toronto, Toronto, ON, Canada
9. Division of Nephrology, The Hospital for Sick Children, Toronto, ON, Canada
10. Division of Nephrology, University Health Network, Toronto, ON, Canada
11. Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON, Canada

Author	ORCID
Samantha J. Anthony	0000-0002-1800-2333
Sarah J. Pol	0000-0003-1883-1753
Jia Lin	0000-0002-8691-3358
Melanie Barwick	0000-0002-2478-604X
Michael Brudno	0000-0001-7947-2243
Rulan S. Parekh	0000-0001-6313-5752
Jennifer Stinson	0000-0002-9969-8052

Corresponding author

Samantha J. Anthony
 The Hospital for Sick Children
 686 Bay Street, Toronto, Ontario, M5G 0A4
 E-mail: samantha.anthony@sickkids.ca

Word count: 3255

Abstract

Introduction:

Patient-reported outcome measures (PROMs) provide an opportunity for meaningful patient engagement and shared decision-making. The objective of this research program is to improve health outcomes for pediatric solid organ transplant patients by implementing PROMs into clinical care. The current study aims to create Voxe, a pediatric user-centred electronic PROM platform, by engaging pediatric patients and healthcare providers throughout the design and development process.

Methods and analysis:

The creation of Voxe will occur over two phases that build on previous research. The user interface design phase will employ a 'user-centric' approach to identify end-users' needs and iteratively refine the look and layout of Voxe to meet these needs. Transplant recipients and healthcare providers will participate in three rounds of testing. During virtual sessions, participants will: (1) complete task-based activities (outcomes – effectiveness and efficiency), (2) complete questionnaires (outcome – satisfaction), and (3) participate in a semi-structured interview. The following phase will involve software development and Voxe usability testing. Transplant recipients and healthcare providers will participate in four rounds of iterative testing. The think-aloud technique will be employed, and participants will describe their thoughts and feelings while interacting with a Voxe prototype to complete structured tasks. Participants will: (1) log into Voxe and complete tasks (outcomes – participant compliance, time on task, successful task completion, frequency of critical and non-critical errors and error-free

1
2
3 rate), and (2) participate in a semi-structured interview. Findings will result in the creation and
4
5 launch of a user-centred electronic PROM platform prototype.
6
7

8 **Ethics and dissemination:**

9

10 Research ethics board approval has been provided by The Hospital for Sick Children. This
11
12 research is critical to answering methodological and operational questions that will inform Voxe
13
14 implementation in pediatric clinical settings and facilitate PROM data collection. Future
15
16 investigations will include an implementation-effectiveness evaluation of the Voxe platform.
17
18
19
20
21
22

23 **Article Summary – Strengths and limitations of this study**

24

- 25 • By engaging pediatric patients and healthcare providers throughout the design and
26
27 development process, this study will facilitate the creation and launch of an evidence-
28
29 based pediatric user-centred electronic PROM platform prototype called Voxe
30
31
- 32 • A 'user-centric' approach will consider the needs of pediatric patients and healthcare
33
34 providers at each design phase and allow for iterative modification of wireframes to
35
36 best meet their identified needs.
37
38
- 39 • The think-aloud technique will facilitate understanding of the end-user's experience
40
41 with Voxe by enabling participants to verbalize their thoughts and feelings while
42
43 interacting with Voxe to complete specific tasks.
44
45
- 46 • As the ability to speak and read English is a requirement for study participation, the
47
48 perspectives of those who are not able to speak and read English will be missed in these
49
50 phases of the study.
51
52
53
54
55
56
57
58
59
60

- 1
2
3 • This study builds the foundation for future phases of research which will include
4
5 healthcare provider Voxe orientation and competency training and an implementation-
6
7 effectiveness evaluation.
8
9

10
11 **Keywords**
12

- 13 • Quality in health care
14
15 • Transplant medicine
16
17
18 • Mental health
19
20
21 • Paediatrics
22
23 • Paediatric transplant surgery
24
25
26 • Qualitative research
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BACKGROUND

For children with end-stage organ failure, transplantation is a life-saving therapy.(1, 2) However, evaluating the success of solid organ transplantation based solely on objective clinical outcomes is insufficient. The patient's subjective assessment is a crucial component in evaluating the burden of disease and can be captured via patient-reported outcome measures (PROMs).(1, 2) PROMs are defined as: "any report of the patient's health condition that comes directly from the patient, without interpretation of the patient's response by a clinician or anyone else" (pg. 2).(3) PROMs can capture a patient's self-assessment of functional status, symptoms, treatment adherence, and multiple domains of well-being and quality of life.(4, 5) In doing so, PROMs give patients a voice in their healthcare and provide an opportunity for meaningful engagement.(6) Research indicates that the systematic collection of PROM data enhances patient-clinician communication and shared decision-making, thereby improving health outcomes.(4, 5, 7, 8) The inclusion of PROMs in clinical care assists in identifying valuable information about the impact of transplantation on patients' symptoms as well as their functional and emotional status. This in turn may help healthcare providers to detect under- and unrecognized problems (e.g., depression, anxiety), resulting in more effective patient care (e.g., initiation of clinical interventions) and an efficient healthcare system.

Innovative opportunities to integrate PROMs into clinical practice have been buoyed by recent advances in eHealth.(9, 10) In particular, the development and implementation of electronic PROMs (ePROMs) can help identify important, patient-valued concerns at the point of care, supporting the delivery of appropriate and timely interventions. Moreover, current platforms that support the use of ePROMs are underdeveloped and require better

1
2
3 implementation with clinical care.(2, 6, 7) Further, research on the implementation
4
5 effectiveness of ePROMs in pediatric clinical settings is limited,(2, 11) giving rise to concerns
6
7 that ePROMs may languish, unused, and fail to realize meaningful outcomes for patients.
8
9
10 Implementation of evidence-based interventions is important to ensure meaningful patient
11
12 outcomes.(12) Achieving optimal clinical and health system outcomes for ePROMS will require
13
14 more intentional and explicit study of how they might best be implemented prior to
15
16
17
18 widespread implementation.(1, 2, 5)
19

20 The overarching objective of this research program is to improve health outcomes and
21
22 transform the delivery of care for pediatric transplant patients in Canada by integrating
23
24 ePROMs into standard clinical practice. This program of research uses a phased approach to
25
26 target the methodological and practical decisions (e.g., determining which standardized PROMs
27
28 to use, identifying goals for collecting PROMs, selecting patients, setting, and timing of
29
30 assessment, etc.) needed to guide systematic and effective implementation of ePROMs into
31
32 'real-world' pediatric patient care settings.(13) Recently completed foundational research to
33
34 explore these questions within pediatric solid organ transplantation consisted of the three
35
36 phases of work outlined below.
37
38
39
40
41

42 **Phase 1: Systematic review**

43
44 A systematic review was conducted to identify PROMs used in pediatric solid organ
45
46 transplantation.(14) A total of 4,305 studies were identified, of which 62 describing 47 PROMs
47
48 were selected for analysis and were appraised for adherence to internationally recommended
49
50 guidelines for item generation, item reduction, and psychometric properties.(15) Findings
51
52 revealed six standardized PROMs that had undergone psychometric evaluation in a pediatric
53
54
55
56
57
58
59
60

1
2
3 solid organ transplant population. This phase of work identified standardized PROMs to
4
5 consider for implementation into clinical care.
6
7

8 **Phase 2: Interviews with key stakeholders**

9

10 Interviews with key stakeholders across Canada, including: (a) pediatric solid organ
11
12 transplant recipients, (b) parent(s)/caregiver(s), and (c) healthcare providers, were conducted
13
14 to explore perspectives regarding ePROMs implementation into clinical practice.⁽¹⁶⁾ Sixty-three
15
16 participants across five Canadian pediatric transplant centres were interviewed, among whom
17
18 nearly all (60/63; 95%) were supportive of implementing an ePROM system into clinical practice
19
20 with the primary goals of: (1) integrating the transplant patient's overall well-being into the
21
22 clinical care conversation, (2) capturing the patient's voice and increasing patient engagement,
23
24 and (3) informing pediatric transplant clinical care. Insights for effective PROM implementation
25
26 included the remote completion of ePROMs in advance of clinical appointments for patients
27
28 eight to 10 years of age or older.
29
30
31
32
33

34 **Phase 3: Consensus workshop**

35

36 A two-day consensus workshop was hosted in December 2018 in Toronto to further
37
38 explore how ePROMs could best be implemented into pediatric transplant clinical practice.
39
40 Workshop proceedings were informed by the results of Phases 1 and 2. The workshop was
41
42 attended by 25 leading experts in the fields of pediatric solid organ transplantation, PROMs,
43
44 implementation science, and computational medicine, as well as patients, caregivers,
45
46 healthcare providers, researchers, and administrators from across Canada. Workshop outcomes
47
48 included: (1) consensus on key methodological and operational decisions for implementing
49
50 ePROMs into practice (e.g. which standardized PROMS to utilize, the setting and timing of
51
52
53
54
55
56
57
58
59
60

1
2
3 assessment, as well as the mode for administering ePROMs), (2) a research plan to design,
4
5 develop and evaluate the usability and implementation of an ePROM platform, and (3) a
6
7 knowledge translation strategy to disseminate research findings to key knowledge users (e.g.
8
9 newsletter, peer-reviewed publications, website posting, national and international
10
11 presentations). The consensus workshop captured attendees' perspectives on practice and
12
13 systems-based facilitators and barriers to implementing ePROMs and was instrumental in
14
15 ensuring that future research would be relevant and meaningful to stakeholders.
16
17
18
19

20 **Study objectives**

21
22 Results from Phases 1 to 3 inform the current study, Phases 4 and 5.(17) The
23
24 overarching aim of the proposed study, which will be conducted within the Transplant and
25
26 Regenerative Medicine Centre at The Hospital for Sick Children (SickKids), is to create an
27
28 ePROM platform called Voxe, that will capture and implement patient-reported outcomes into
29
30 the clinical care workflow for pediatric organ transplant patients. Specifically, Phase 4 aims to
31
32 design the user interfaces of the Voxe platform, and Phase 5 aims to develop the Voxe software
33
34 and conduct usability testing of Voxe in preparation for a future implementation-effectiveness
35
36 trial (Phase 6). A graphical representation of the different research phases is displayed in Figure
37
38
39
40 *1: Measuring What Matters: Implementing Patient-Reported Outcome Measures into Clinical*
41
42
43
44
45 *Practice – A Research Program.*
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

METHODS

Phase 4: User interface design of Voxe ePROM platform

eHealth technologies designed and developed based on assumptions of end-user motivations, goals or needs, are often less effective than those that engage end-users throughout the process.(10, 18) Thus, a 'user-centric' approach in which end-users (i.e., patients and healthcare providers) are central to the design process will guide the design and development of Voxe. This evidence-based approach will consider the needs of Voxe users at each design phase and will allow for iterative modification of wireframes to best meet their identified needs.(19) A 'user-centric' approach is paramount for user engagement with the platform, ultimately contributing to the effectiveness of the platform itself.(10)

Study participants and inclusion criteria

Purposive sampling will be used to recruit 12 patient participants across age, organ type, sex, gender, and ethnicity from the Transplant and Regenerative Medicine Centre at SickKids to obtain maximum variation.(20) Twelve members of the patients' interdisciplinary healthcare teams at SickKids will also be recruited purposively across professional disciplines, years of practice, sex, gender and ethnicity. This sample size is consistent with testing methods for clinical information systems.(21)

Patients eligible to participate include those who are: (a) 10 to 17 years of age, (b) able to speak and read English, and (c) heart, kidney, liver or lung transplant recipients who are a minimum of three months post-transplant. Patients with significant cognitive impairments, as determined by a healthcare team member, will not be invited to participate. Eligible healthcare

1
2
3 providers include any member of the interdisciplinary healthcare team within the Transplant
4
5 and Regenerative Medicine Centre at SickKids.
6

7 8 Procedures and outcomes 9

10 The design of preliminary Voxe wireframes will be guided by: (1) stakeholder input
11
12 gleaned from previous phases of research,(14, 16) and (2) design workshop processes, including
13
14 identification of Voxe users (i.e., patients and healthcare providers) and the tasks they will
15
16 complete on their respective platforms (i.e., persona and task inventory development).
17

18 Following the design of preliminary wireframes, a rapid and iterative testing methodology will
19
20 be used to evaluate, learn and improve Voxe prior to development (i.e., coding and launch).(19)
21
22

23 Three rounds of testing sessions will be scheduled with patient and healthcare provider
24
25 participants to elicit feedback on Voxe design features. Written consent and assent, as well as
26
27 demographic information, will be obtained prior to study participation.
28
29

30 Each testing session will be conducted virtually via the Personal Health Information
31
32 Protection Act-compliant version of Zoom or Microsoft Teams. During each session,
33
34 International Organization for Standardization key performance indicators, consensus-base
35
36 standards for technology, will be benchmarked and tracked to validate each iteration for
37
38 success.(22, 23) In particular, objective and subjective standards common in user experience
39
40 design testing,(24) will be collected to measure: (1) effectiveness – accuracy and completeness
41
42 with which users achieve specific goals, displayed as a percentage of tasks successfully
43
44 completed by users, and (2) efficiency – resources used in relation to results achieved,
45
46 represented by the time it takes users to successfully complete the task.(25) Prior to the
47
48 scheduled testing session, the URL for the testing website will be emailed to the participant.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 During the session, participants will complete task-based activities using incremental segments
4
5 (i.e., wireframes) of the Voxe platform.
6
7

8 Following the task-based activities, healthcare provider participants will complete a
9
10 Likert scale questionnaire to assess the key performance indicator satisfaction. Patient
11
12 participant's overall impression and experience with the Voxe platform will be evaluated using
13
14 the Microsoft Desirability Toolkit.(26) Patient participants will select five words from a list of
15
16 product reaction words to describe their attitude towards the Voxe platform. Product reaction
17
18 words, such as "fun" and "calm" describe intangible emotional response towards the
19
20 interface.(27)
21
22
23

24
25 Lastly, participants will share their likes and dislikes of the Voxe platform design and
26
27 comment on the platform's ease of use and elements of functionality during a virtual semi-
28
29 structured qualitative interview. Semi-structured interviews foster reciprocity between the
30
31 participant and interviewer, allow the interviewer to ask pertinent follow-up questions to elicit
32
33 rich data and enable the participant to express themselves using their own words.(28-30) The
34
35 interview guide will be developed by the study team and will be informed by clinical knowledge
36
37 and experience. Interviews will be conducted by study team members trained in qualitative
38
39 methods. Sessions will be audio-recorded, transcribed verbatim and de-identified to protect
40
41 participant confidentiality. Recruitment for Phase 4 began in May 2020.
42
43
44
45

46 47 Data analysis 48

49 Data collected during the testing sessions, including objective and subjective
50
51 International Organization for Standardization key performance indicators, will be used to
52
53 refine Voxe. The research team will utilize content and thematic analysis to categorize the data
54
55
56
57
58
59
60

1
2
3 collected during qualitative interviews.(31-33) Two members of the study team experienced in
4
5 qualitative methods, will code the data independently, and categories will be reviewed and
6
7 refined until consensus is reached for emerging themes. Trustworthiness will be achieved by
8
9 facilitating member checking and soliciting rich description during interviews, as well as hosting
10
11 frequent team meetings to support in-depth, iterative analysis with reflexive discussion among
12
13 team members. Analysis will be complete once the research team agrees that thematic
14
15 saturation is attained.(33) NVivo 12 will be used to manage qualitative data.(34) Quantitative
16
17 data collected during the testing sessions will be triangulated with qualitative themes to
18
19 provide a richer understanding of end-users' experience with Voxe. Refinements will be made
20
21 to the Voxe platform design based on the triangulated data. Three rounds of iterative feedback
22
23 testing will be conducted with each participant population (i.e. four participants per round)
24
25 until Voxe is considered acceptable to participating end-users with no further refinements
26
27 identified.(35, 36) Following the third round of patient and healthcare provider iterative testing,
28
29 the design team will share the final Voxe patient and healthcare provider annotated wireframes
30
31 with the development team.

Phase 5: Development of ePROM platform Voxe and usability testing

41
42 Usability is defined as the “extent to which a system, product or service can be used by
43
44 specified users to achieve specified goals with effectiveness, efficiency and satisfaction in a
45
46 specified context of use”.(22) To test Voxe usability, the think-aloud technique will be
47
48 employed in which participants will verbalize their thoughts and feelings while interacting with
49
50 Voxe to complete structured tasks.(37, 38) The think-aloud technique is integral to
51
52 understanding the end-user experience with Voxe and will highlight potential barriers to Voxe
53
54
55
56
57
58
59
60

1
2
3 adoption that can inform its subsequent implementation.(37, 38) Semi-structured interviews
4
5 and data analytics, described below, will also be conducted.(39)
6
7

8 Study participants and inclusion criteria 9

10 Purposive sampling will be used to recruit 12 to 20 patient participants across age,
11
12 organ type, sex, gender, and ethnicity from the Transplant and Regenerative Medicine Centre
13
14 at SickKids. Twelve to 20 members of the patients' interdisciplinary healthcare team will also be
15
16 recruited purposively across professional disciplines, years of practice, sex, gender and
17
18 ethnicity.(21)
19
20
21

22 Patients eligible to participate will include those who are: (a) eight to 17 years of age
23
24 with capacity to assent/consent, (b) those able to speak and read English, (c) heart, kidney, liver
25
26 or lung transplant recipients, and (d) who are a minimum of three months post-transplant.
27
28 Informed consent will be obtained from the parents/legal guardians of participants who
29
30 provide assent. Eligible healthcare providers include any member of the interdisciplinary
31
32 healthcare team within the Transplant and Regenerative Medicine Centre at SickKids who have
33
34 worked within their position for a minimum of six months.
35
36
37
38
39

40 Procedures and outcomes 41

42 Following Phase 4, the development team will use the Voxe patient and healthcare
43
44 provider annotated wireframes to develop the respective interfaces of the Voxe ePROM
45
46 platform, using an agile, scrum framework.(19) Feature development will be phased and will
47
48 include authentication, user dashboards, account settings, privacy/security controls and survey
49
50 submission/review functionality.
51
52
53
54
55
56
57
58
59
60

1
2
3 Four rounds of iterative testing will be completed with three to five patients and three
4
5 to five healthcare providers per round, as is consistent with usability testing methods for clinical
6
7 information systems.(21) The first two rounds will be conducted in-person or virtual with a
8
9 member of the study team, using smartphones, tablets and/or computers. Both patient and
10
11 healthcare provider participants will be asked to complete a core set of tasks on Voxe which will
12
13 be presented to them in the form of scenarios that they may encounter while interacting with
14
15 Voxe. For example, patients will be provided with an anonymous username and password,
16
17 invited to successfully log into Voxe, and navigate Voxe to complete available ePROMs (i.e.
18
19 PedsQL™ Generic Core Scales(40)). Healthcare providers will be invited to navigate Voxe to
20
21 view and interpret sample ePROM results. Employing think-aloud methodology, participants
22
23 will be encouraged to voice out loud what they are looking at, thinking, doing and feeling as
24
25 they navigate the platform.(37, 39)
26
27
28
29
30
31

32 The last two testing rounds will be conducted to simulate 'real-world' settings.
33
34 An automated text message or email with an embedded hyperlink will be sent to patients
35
36 asking them to access Voxe remotely on a smartphone, tablet or computer. Patients will
37
38 independently log into Voxe using an anonymous username and password and navigate the
39
40 platform to complete available ePROMs. Healthcare providers will be asked to access Voxe on a
41
42 computer and independently navigate the Voxe platform to view and interpret ePROM data
43
44 entered by patients.
45
46
47
48

49 Objective measures to be collected include: (1) participant compliance, (2) time on task,
50
51 (3) successful task completion (fidelity), (4) frequency of critical errors, (5) frequency of non-
52
53 critical errors, and (6) error-free rate.(41) Following each testing round, in-person or virtual
54
55
56
57
58
59
60

1
2
3 semi-structured interviews will be conducted to ascertain what participants liked or disliked
4
5 and why, ease of use, elements of functionality in the context of typical practice workflow, as
6
7 well as suggestions for improvements. Iterative usability testing will also be conducted until
8
9 Voxe is considered acceptable to participating end-users with no further refinements
10
11 identified.(35, 36) Interviews will be audio-recorded, transcribed verbatim and de-identified.
12
13

14 15 Data analysis

16
17 Quantitative data including participant compliance, time on task, successful task
18
19 completion, frequency of critical and non-critical errors, and error-free rate will be analyzed.
20
21 Similar to Phase 4, qualitative interviews will be subject to content and thematic analysis to
22
23 identify emerging themes.(31, 32) Themes will be coded and categorized using NVivo 12
24
25 according to type and frequency of occurrence.(34) Quantitative and qualitative data will be
26
27 triangulated to inform changes made to the Voxe platform.
28
29
30
31

32 33 Patient and public involvement

34
35 Phases 4 and 5 are informed by the invaluable feedback provided by stakeholders,
36
37 including pediatric patients, their caregivers and healthcare providers, from previous phases of
38
39 research.(16) Patients' and healthcare providers' thoughts, feelings and perspectives about
40
41 Voxe captured through research processes described in this protocol will continue to guide this
42
43 research program. Stakeholder involvement will ensure the implementation of evidence-based
44
45 interventions integral to achieving meaningful patient outcomes.
46
47
48

49 50 ETHICS AND DISSEMINATION

51 52 Ethics approval and consent to participate

1
2
3 Institutional research ethics board approval has been provided by SickKids (REB number:
4
5 1000057043 (Phase 4); REB number: 1000067700 (Phase 5)). All participants will provide
6
7 informed consent or assent prior to their involvement in the study. For participants who
8
9 provide informed assent, informed consent will be obtained from the parents/legal guardians
10
11 prior to study participation.
12
13

14 15 **Information security**

16
17 All interviews will be audio recorded and transcribed verbatim. Transcription will be completed
18
19 by a member of the study team. All transcriptions will be de-identified to protect participant
20
21 confidentiality. All identifying information, both paper copy and electronic information, will be
22
23 kept confidential. Use of data over the course of the study and dissemination of results will
24
25 follow standard practice guidelines as determined by the SickKids Research Institute.
26
27
28

29 30 **Discussion and dissemination**

31
32 The collection of PROMs provides the opportunity to incorporate patient-centred
33
34 perspectives into pediatric clinical practice.(2, 6, 11, 42-45) The creation of the Voxe ePROM
35
36 platform will reform the practice of pediatric medicine by enhancing the capacity of patient-
37
38 provider partnerships to identify and address issues that are most meaningful to patients.(46)
39
40 The design and development of Voxe outlined in this protocol are critical to answering
41
42 important methodological and operational questions that will inform the implementation of
43
44 ePROMs in pediatric clinical settings.
45
46
47

48
49 Engaging patients and healthcare providers throughout Voxe design and development
50
51 will result in the creation and launch of a user-centred ePROM platform. For patients, Voxe will
52
53 facilitate ePROM data collection in a child friendly and patient-centred manner. For healthcare
54
55
56
57
58
59

1
2
3 providers, Voxe will facilitate convenient and timely review of patient ePROM data,
4
5 collaboration within healthcare teams, and shared decision-making discussions between
6
7 healthcare providers and patients during clinical encounters.
8
9

10 During Phase 4, patients and healthcare providers will share their likes and dislikes of
11 the design and comment on Voxe functionality and ease of use. It is critical that Voxe design
12 iterations integrate this feedback, as the interface needs to be designed in a way that is logical,
13 intuitive, and user friendly for end-users. This process will ensure that there is an evidence-
14 based iterative design in place before usability testing. In Phase 5, patients and healthcare
15 providers will comment on what they liked or disliked about Voxe and why, Voxe ease of use,
16 and elements of functionality in the context of typical practice workflow, as well as suggestions
17 to improve Voxe. Voxe will be further refined according to this feedback until a final version is
18 produced. The final product will enhance the experience of end-users with systematically
19 tested functionality and design. Following the procedures outlined above, creating an evidence-
20 based ePROM platform will enable these outcomes. Findings from this study will be widely
21 disseminated through infographics, posts on the research team's website, peer-reviewed
22 journal publications and presentations at patient and family educational events as well as
23 scientific and academic conferences. Data collection is expected to be completed by the end of
24 2021 with publication of results in early 2022.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 This research lays the groundwork for future investigations that will include Voxe
47 healthcare provider orientation and competency training as part of a more comprehensive
48 implementation plan. Additionally, an implementation-effectiveness evaluation (Phase 6) of the
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Voxe ePROM platform will be conducted to explore how Voxe can be effectively implemented
4
5
6 in a manner that impacts pediatric transplantation patient's health outcomes and clinical care.
7

8 **List of abbreviations**

9 ePROM – Electronic patient-reported outcome measure

10 PROM – Patient-reported outcome measure
11
12

13 ***Acknowledgements***

14 The authors thank our patient partners and past and future research participants.
15
16

17 ***Competing interests***

18 The authors declare that they have no competing interests.
19
20

21 ***Funding***

22 This study was supported by the SickKids Transplant and Regenerative Medicine Centre and
23 Astellas Pilot Grant (Grant/Award Number: Not Applicable), the Canadian Donation and
24 Transplantation Research Program Innovation Grant (Grant/Award Number: Not Applicable)
25 and the Health Canada Health Care Policy Contribution Program (Grant/Award Number: 1920-
26 HQ-000105).
27
28

29 ***Authors' contributions***

30 All authors contributed to project conception and study design. SJA, SJP and JL drafted the
31 manuscript. All authors read the manuscript and gave final approval of the version to be
32 published.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Rossano JW, Cherikh WS, Chambers DC, et al. The international thoracic organ transplant registry of the International Society for Heart and Lung Transplantation: Twenty-first pediatric heart transplantation report—2018; Focus theme: Multiorgan transplantation. *J Heart Lung Transplant* 2018;37(10):1184-95.
2. Bevans KB, Moon J, Carle AC, et al. Patient reported outcomes as indicators of pediatric health care quality. *Acad Pediatr* 2014;14(5):S90-S96.
3. US Department of Health Human Services Food and Drug Administration. Guidance for industry - Patient-reported outcome measures: Use in medical product development to support labeling claims. *Fed Reg* 2009;74(235):65132–33.
4. Santana M-J, Feeny D. Framework to assess the effects of using patient-reported outcome measures in chronic care management. *Qual Life Res* 2014;23(5):1505-13.
5. Fung CH, Hays RD. Prospects and challenges in using patient-reported outcomes in clinical practice. *Qual Life Res* 2008;17(10):1297-302.
6. Bitton A, Onega T, Tosteson AN, et al. Toward a better understanding of patient-reported outcomes in clinical practice. *Am J Manag Care* 2014;20(4):281.
7. Nelson EC, Eftimovska E, Lind C, et al. Patient reported outcome measures in practice. *BMJ* 2015;350
8. Valderas J, Kotzeva A, Espallargues M, et al. The impact of measuring patient-reported outcomes in clinical practice: A systematic review of the literature. *Qual Life Res* 2008;17(2):179-93.
9. Forrest CB. Digitization of patient-reported outcomes. *Value Health* 2013;16(4):459-60. doi: 10.1016/j.jval.2013.05.005
10. McCurdie T, Taneva S, Casselman M, et al. mHealth consumer apps: The case for user-centered design. *Biomed Instrum Technol* 2012;46(Suppl 2):49-56.
11. Huang I-C, Revicki DA, Schwartz CE. Measuring pediatric patient-reported outcomes: Good progress but a long way to go: Springer, 2014.
12. Hoffmann T, Bennett S, Del Mar C. Evidence-based practice across the health professions-e-book: Elsevier Health Sciences 2013.
13. Aaronson N, Elliott T, Greenhalgh J, et al. User's guide to implementing patient-reported outcomes assessment in clinical practice version 2. In: Research ISfQoL, ed., 2015.
14. Anthony SJ, Stinson H, Lazor T, et al. Patient-reported outcome measures within pediatric solid organ transplantation: A systematic review. *Pediatr Transplant* 2019;23(6):e13518.
15. Terwee CB, Mokkink LB, Knol DL, et al. Rating the methodological quality in systematic reviews of studies on measurement properties: A scoring system for the COSMIN checklist. *Qual Life Res* 2012;21(4):651-57.
16. Anthony SJ, Young K, Pol SJ, et al. Patient-reported outcome measures in pediatric solid organ transplantation: Exploring stakeholder perspectives on clinical implementation through qualitative description. *Qual Life Res* 2021 doi: 10.1007/s11136-020-02743-8 [published Online First: 2021/01/16]
17. Meyers DC, Durlak JA, Wandersman A. The quality implementation framework: A synthesis of critical steps in the implementation process. *Am J Community Psychol* 2012;50(3-4):462-80.

18. Verhoeven F, Tanja-Dijkstra K, Nijland N, et al. Asynchronous and synchronous teleconsultation for diabetes care: A systematic literature review. *J Diabetes Sci Technol* 2010;4(3):666-84.
19. Barnum CM. Chapter 1: Establishing the essentials. In: Merken S, ed. Usability testing essentials: ready, set test! 2 ed. Amsterdam: Elsevier 2020:9-33.
20. Palinkas LA, Horwitz SM, Green CA, et al. Purposeful sampling for qualitative data collection and analysis in mixed method implementation research. *Adm Policy Ment Health* 2015;42(5):533-44. doi: 10.1007/s10488-013-0528-y
21. Kushniruk AW, Patel VL. Cognitive and usability engineering methods for the evaluation of clinical information systems. *J Biomed Inform* 2004;37(1):56-76.
22. International Organization for Standardization. ISO 9241-11:2018(en) Ergonomics of human-system interaction — Part 11: Usability: Definitions and concepts 2018 [Available from: <https://www.iso.org/obp/ui/#iso:std:iso:9241:-11:ed-2:v1:en> accessed January 20 2021.
23. International Organization for Standardization. About us: What we do [Available from: <https://www.iso.org/what-we-do.html> accessed January 20 2021.
24. Barnum CM. Chapter 8: Analyzing the findings. In: Merken S, ed. Usability testing essentials: ready, set test! 2 ed. Amsterdam: Elsevier 2020:287-319.
25. International Organization for Standardization. ISO 9000:2015(en) Quality management systems — Fundamentals and vocabulary 2015 [Available from: <https://www.iso.org/obp/ui/#iso:std:iso:9000:ed-4:v1:en> accessed January 20 2021.
26. Barnum C. Chapter 6: Preparing for usability testing. In: Merken S, ed. Usability testing essentials: ready, set test! 2 ed. Amsterdam: Elsevier 2020:197-248.
27. Benedek J, Miner T. Measuring desirability: New methods for evaluating desirability in a usability lab setting. *Usability Professionals Association* 2002;2003(8-12):57.
28. Galletta A. Mastering the semi-structured interview and beyond: From research design to analysis and publication: NYU Press 2013.
29. Rubin HJ, Rubin IS. Qualitative interviewing: The art of hearing the data. 2 ed. Thousand Oaks, CA: SAGE 2005.
30. Kallio H, Pietilä AM, Johnson M, et al. Systematic methodological review: Developing a framework for a qualitative semi-structured interview guide. *J Adv Nurs* 2016;72(12):2954-65.
31. Gibbs G. Analysing qualitative data. London, England: SAGE 2007.
32. Fereday J, Muir-Cochrane E. Demonstrating rigor using thematic analysis: A hybrid approach of inductive and deductive coding and theme development. *Int J Qual Methods* 2006;5(1):80-92.
33. Elo S, Kyngäs H. The qualitative content analysis process. *J Adv Nurs* 2008;62(1):107-15. doi: 10.1111/j.1365-2648.2007.04569.x [published Online First: 2008/03/21]
34. Richards L. Using NVivo in qualitative research: Sage 1999.
35. Stinson JN, Jibb LA, Nguyen C, et al. Development and testing of a multidimensional iPhone pain assessment application for adolescents with cancer. *J Med Internet Res* 2013;15(3):e51.
36. Macefield R. How to specify the participant group size for usability studies: A practitioner's guide. *J Usability Stud* 2009;5(1):34-45.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
37. Li AC, Kannry JL, Kushniruk A, et al. Integrating usability testing and think-aloud protocol analysis with “near-live” clinical simulations in evaluating clinical decision support. *Int J Med Inform* 2012;81(11):761-72.
 38. Rose AF, Schnipper JL, Park ER, et al. Using qualitative studies to improve the usability of an EMR. *J Biomed Inform* 2005;38(1):51-60.
 39. Lewis C. Using the “think aloud” method in cognitive interface design. *New York: IBM* 1982
 40. Varni J, Seid M, Kurtin P. PedsQL TM 4.0: Reliability and validity of the Pediatric Quality of Life Inventory TM Version 4.0 Generic Core Scales in healthy and patient populations. *Med Care* 2001;39:800-12.
 41. US General Services Administration Technology Transformation Services. Planning a Usability Test 2021 [Available from: <https://www.usability.gov/how-to-and-tools/methods/planning-usability-testing.html> accessed January 20 2021.
 42. Calvert M, Kyte D, Price G, et al. Maximising the impact of patient reported outcome assessment for patients and society. *BMJ* 2019;364
 43. Haverman L, Engelen V, van Rossum MA, et al. Monitoring health-related quality of life in paediatric practice: Development of an innovative web-based application. *BMC Pediatr* 2011;11(1):1-7.
 44. Haywood K, Brett J, Salek S, et al. Patient and public engagement in health-related quality of life and patient-reported outcomes research: What is important and why should we care? Findings from the first ISOQOL patient engagement symposium. *Qual Life Res* 2015;24(5):1069-76.
 45. Cleemput I, Dobbels F. Measuring patient-reported outcomes in solid organ transplant recipients. *Pharmacoeconomics* 2007;25(4):269-86.
 46. Engelen V, Detmar S, Koopman H, et al. Reporting health-related quality of life scores to physicians during routine follow-up visits of pediatric oncology patients: Is it effective? *Pediatr Blood Cancer* 2012;58(5):766-74.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Figure 1: Measuring What Matters: Implementing Patient-Reported Outcome Measures into Clinical Practice – A Research Program



For peer review only

GUIDED – a guideline for reporting for intervention development studies.

Supplementary File 1: Blank Checklist

Item description	Explanation	Page in manuscript where item is located	Other*
1. Report the context for which the intervention was developed.	Understanding the context in which an intervention was developed informs readers about the suitability and transferability of the intervention to the context in which they are considering evaluating, adapting or using the intervention. Context here can include place, organisational and wider socio-political factors that may influence the development and/or delivery of the intervention (15).	9, 10, 13, 14	
2. Report the purpose of the intervention development process.	Clearly describing the purpose of the intervention specifies what it sets out to achieve. The purpose may be informed by research priorities, for example those identified in systematic reviews, evidence gaps set out in practice guidance such as The National Institute for Health and Care Excellence or specific prioritisation exercises such as those undertaken with patients and practitioners through the James Lind Alliance.	8	
3. Report the target population for the intervention development process.	The target population is the population that will potentially benefit from the intervention – this may include patients, clinicians, and/or members of the public. If the target population is clearly described then readers will be able to understand the relevance of the intervention to their own research or practice. Health inequalities, gender and ethnicity are features of the target population that may be relevant to intervention development processes.	9, 10, 13, 14	
4. Report how any published intervention development approach contributed to the development process	Many formal intervention development approaches exist and are used to guide the intervention development process (e.g. 6Squid (16) or The Person Based Approach to Intervention Development (17)). Where a formal intervention development approach is used, it is helpful to describe the process that was followed, including any deviations. More general approaches to intervention development also exist and have been categorised as follows (3):- Target Population-centred intervention development; evidence and theory-based intervention development; partnership intervention development; implementation-based intervention development; efficacy-based intervention development; step or phased-based intervention development; and intervention-specific intervention development (3). These approaches do not always have specific guidance that describe their use. Nevertheless, it is helpful to give a rich description of how any published approach was operationalised	9, 13, 14	
5. Report how evidence from different sources informed the intervention development process.	Intervention development is often based on published evidence and/or primary data that has been collected to inform the intervention development process. It is useful to describe and reference all forms of evidence and data that have informed the development of the intervention because evidence bases can change rapidly, and to explain the manner in which the evidence and/or data was used. Understanding what evidence was and was not available at the time of intervention development can help readers to assess transferability to their current situation.	6-8	
6. Report how/if published theory informed the intervention development process.	Reporting whether and how theory informed the intervention development process aids the reader's understanding of the theoretical rationale that underpins the intervention. Though not mentioned in the e-Delphi or consensus meeting, it became increasingly apparent through the development of our guidance that this theory item could relate to either existing published theory or programme theory	5, 6, 9, 13, 14	
7. Report any use of components from an existing intervention in the current intervention development process.	Some interventions are developed with components that have been adopted from existing interventions. Clearly identifying components that have been adopted or adapted and acknowledging their original source helps the reader to understand and distinguish between the novel and adopted components of the new intervention.	5, 6	
8. Report any guiding principles, people or factors that were prioritised when making decisions during the intervention development process.	Reporting any guiding principles that governed the development of the application helps the reader to understand the authors' reasoning behind the decisions that were made. These could include the examples of particular populations who views are being considered when designing the intervention, the modality that is viewed as being most appropriate, design features considered important for the target population, or the potential for the intervention to be scaled up.	5-8	

Item description	Explanation	Page in manuscript where item is located	Other*
9. Report how stakeholders contributed to the intervention development process.	Potential stakeholders can include patient and community representatives, local and national policy makers, health care providers and those paying for or commissioning health care. Each of these groups may influence the intervention development process in different ways. Specifying how differing groups of stakeholders contributed to the intervention development process helps the reader to understand how stakeholders were involved and the degree of influence they had on the overall process. Further detail on how to integrate stakeholder contributions within intervention reporting are available (19).	6-11, 13-15	
10. Report how the intervention changed in content and format from the start of the intervention development process.	Intervention development is frequently an iterative process. The conclusion of the initial phase of intervention development does not necessarily mean that all uncertainties have been addressed. It is helpful to list remaining uncertainties such as the intervention intensity, mode of delivery, materials, procedures, or type of location that the intervention is most suitable for. This can guide other researchers to potential future areas of research and practitioners about uncertainties relevant to their healthcare context.	N/A	
11. Report any changes to interventions required or likely to be required for subgroups.	Specifying any changes that the intervention development team perceive are required for the intervention to be delivered or tailored to specific sub groups enables readers to understand the applicability of the intervention to their target population or context. These changes could include changes to personnel delivering the intervention, to the content of the intervention, or to the mode of delivery of the intervention.	N/A	
12. Report important uncertainties at the end of the intervention development process.	Intervention development is frequently an iterative process. The conclusion of the initial phase of intervention development does not necessarily mean that all uncertainties have been addressed. It is helpful to list remaining uncertainties such as the intervention intensity, mode of delivery, materials, procedures, or type of location that the intervention is most suitable for. This can guide other researchers to potential future areas of research and practitioners about uncertainties relevant to their healthcare context.	N/A	
13. Follow TIDieR guidance when describing the developed intervention.	Interventions have been poorly reported for a number of years. In response to this, internationally recognized guidance has been published to support the high quality reporting of health care? interventions ⁵ and public health interventions ¹⁴ . This guidance should therefore be followed when describing a developed intervention.	N/A	
14. Report the intervention development process in an open access format.	Unless reports of intervention development are available people considering using an intervention cannot understand the process that was undertaken and make a judgement about its appropriateness to their context. It also limits cumulative learning about intervention development methodology and observed consequences at later evaluation, translation and implementation stages. Reporting intervention development in an open access (Gold or Green) publishing format increases the accessibility and visibility of intervention development research and makes it more likely to be read and used. Potential platforms for open access publication of intervention development include open access journal publications, freely accessible funder reports or a study web-page that details the intervention development process.	N/A	

*e.g. if item is reported elsewhere, then the location of this information can be stated here.

BMJ Open

The creation of an electronic patient-reported outcome measure platform Voxe: A mixed methods study protocol in pediatric solid organ transplantation

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-053119.R1
Article Type:	Protocol
Date Submitted by the Author:	01-Sep-2021
Complete List of Authors:	Anthony, Samantha; The Hospital for Sick Children, Child Health Evaluative Sciences; University of Toronto, Factor-Inwentash Faculty of Social Work Pol, Sarah; The Hospital for Sick Children, Child Health Evaluative Sciences Lin, Jia; The Hospital for Sick Children, Child Health Evaluative Sciences Barwick, Melanie; The Hospital for Sick Children, Child Health Evaluative Sciences; University of Toronto, Dalla Lana School of Public Health Brudno, Michael; University Health Network, Data Aggregation, Translation and Architecture; University of Toronto, Faculty of Arts and Science Manase, Dorin; University Health Network, Data Aggregation, Translation and Architecture Parekh, Rulan; The Hospital for Sick Children, Child Health Evaluative Sciences; The Hospital for Sick Children, Transplant and Regenerative Medicine Centre Silva, Amanda; University Health Network, Data Aggregation, Translation and Architecture Stinson, Jennifer; The Hospital for Sick Children, Child Health Evaluative Sciences; University of Toronto, Lawrence S. Bloomberg Faculty of Nursing
Primary Subject Heading:	Paediatrics
Secondary Subject Heading:	Mental health, Health services research, Patient-centred medicine, Qualitative research, Research methods
Keywords:	Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Transplant medicine < INTERNAL MEDICINE, MENTAL HEALTH, PAEDIATRICS, Paediatric transplant surgery < PAEDIATRIC SURGERY, QUALITATIVE RESEARCH

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Title

The creation of an electronic patient-reported outcome measure platform Voxe: A mixed methods study protocol in pediatric solid organ transplantation

Authors

Samantha J. Anthony¹⁻⁴, Sarah J. Pol¹, Jia Lin¹, Melanie Barwick^{1,5,6}, Michael Brudno^{7,8}, Dorin Manase⁷, Rulan S. Parekh^{1,2,9,10}, Amanda Silva⁷, Jennifer Stinson^{1,11}

1. Child Health Evaluative Sciences, Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, Toronto, ON, Canada
2. Transplant and Regenerative Medicine Centre, The Hospital for Sick Children, Toronto, ON, Canada
3. Factor-Inwentash Faculty of Social Work, University of Toronto, Toronto, ON, Canada
4. Canadian Donation and Transplantation Research Program, Edmonton, AB, Canada
5. Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
6. Temerty Faculty of Medicine, Department of Psychiatry, University of Toronto, Toronto, ON, Canada
7. Data Aggregation, Translation and Architecture, University Health Network, Toronto, ON, Canada
8. Faculty of Arts and Science, Department of Computer Science, University of Toronto, Toronto, ON, Canada
9. Division of Nephrology, The Hospital for Sick Children, Toronto, ON, Canada
10. Division of Nephrology, University Health Network, Toronto, ON, Canada
11. Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON, Canada

Author	ORCID
Samantha J. Anthony	0000-0002-1800-2333
Sarah J. Pol	0000-0003-1883-1753
Jia Lin	0000-0002-8691-3358
Melanie Barwick	0000-0002-2478-604X
Michael Brudno	0000-0001-7947-2243
Rulan S. Parekh	0000-0001-6313-5752
Jennifer Stinson	0000-0002-9969-8052

Corresponding author

Samantha J. Anthony
 The Hospital for Sick Children
 686 Bay Street, Toronto, Ontario, M5G 0A4
 E-mail: samantha.anthony@sickkids.ca

Word count: 3386

Abstract

Introduction:

Patient-reported outcome measures (PROMs) provide an opportunity for meaningful patient engagement and shared decision-making. The objective of this research program is to improve health outcomes for pediatric solid organ transplant patients by implementing PROMs into clinical care. The current study aims to create Voxe, a pediatric user-centred electronic PROM platform, by engaging pediatric patients and healthcare providers throughout the design and development process.

Methods and analysis:

The creation of Voxe will occur over two phases that build on previous research. The user interface design phase will employ a 'user-centric' approach to identify end-users' needs and iteratively refine the look and layout of Voxe to meet these needs. Transplant recipients and healthcare providers will participate in three rounds of testing. During virtual sessions, participants will: (1) complete task-based activities (outcomes – effectiveness and efficiency), (2) complete questionnaires (outcome – satisfaction), and (3) participate in a semi-structured interview. The following phase will involve software development and Voxe usability testing. Transplant recipients and healthcare providers will participate in four rounds of iterative testing. The think-aloud technique will be employed, and participants will describe their thoughts and feelings while interacting with a Voxe prototype to complete structured tasks. Participants will: (1) log into Voxe and complete tasks (outcomes – time on task, successful task completion, frequency of critical and non-critical errors and error-free rate), and (2) participate in a semi-structured interview. Findings will result in the creation and launch of a user-centred electronic PROM platform prototype.

Ethics and dissemination:

Research ethics board approval has been provided by The Hospital for Sick Children. This research is critical to answering methodological and operational questions that will inform Voxe implementation in pediatric clinical settings and facilitate PROM data collection. Future investigations will include an implementation-effectiveness evaluation of the Voxe platform.

Article Summary – Strengths and limitations of this study

- By engaging pediatric patients and healthcare providers throughout the design and development process, this study will facilitate the creation and launch of an evidence-based pediatric user-centred electronic PROM platform prototype called Voxe
- A ‘user-centric’ approach will consider the needs of pediatric patients and healthcare providers at each design phase and allow for iterative modification of wireframes to best meet their identified needs.
- The think-aloud technique will facilitate understanding of the end-user’s experience with Voxe by enabling participants to verbalize their thoughts and feelings while interacting with Voxe to complete specific tasks.
- As the ability to speak and read English is a requirement for study participation, the perspectives of those who are not able to speak and read English will be missed in these phases of the study.
- This study builds the foundation for future phases of research which will include healthcare provider Voxe orientation and competency training and an implementation-effectiveness evaluation.

Keywords

- Quality in health care
- Transplant medicine
- Mental health
- Paediatrics
- Paediatric transplant surgery
- Qualitative research

BACKGROUND

For children with end-stage organ failure, transplantation is a life-saving therapy.(1, 2) However, evaluating the success of solid organ transplantation based solely on objective clinical outcomes is insufficient. The patient's subjective assessment is a crucial component in evaluating the burden of disease and can be captured via patient-reported outcome measures (PROMs).(1, 2) PROMs are defined as: "any report of the patient's health condition that comes directly from the patient, without interpretation of the patient's response by a clinician or anyone else" (pg. 2).(3) PROMs can capture a patient's self-assessment of functional status, symptoms, treatment adherence, and multiple domains of well-being and quality of life.(4, 5) In doing so, PROMs give patients a voice in their healthcare and provide an opportunity for meaningful engagement.(6) Research indicates that the systematic collection of PROM data enhances patient-clinician communication and shared decision-making, thereby improving health outcomes.(4, 5, 7, 8) The inclusion of PROMs in clinical care assists in identifying valuable information about the impact of transplantation on patients' symptoms as well as their functional and emotional status. This in turn may help healthcare providers to detect under- and unrecognized problems (e.g., depression, anxiety), resulting in more effective patient care (e.g., initiation of clinical interventions) and an efficient healthcare system.

Innovative opportunities to integrate PROMs into clinical practice have been buoyed by recent advances in eHealth.(9, 10) In particular, the development and implementation of electronic PROMs (ePROMs) can help identify important, patient-valued concerns at the point of care, supporting the delivery of appropriate and timely interventions. Moreover, current platforms that support the use of ePROMs are underdeveloped and require better

1
2
3 implementation with clinical care.(2, 6, 7) Further, research on the implementation
4
5 effectiveness of ePROMs in pediatric clinical settings is limited,(2, 11) giving rise to concerns
6
7 that ePROMs may languish, unused, and fail to realize meaningful outcomes for patients.
8
9
10 Implementation of evidence-based interventions is important to ensure meaningful patient
11
12 outcomes.(12) Achieving optimal clinical and health system outcomes for ePROMS will require
13
14 more intentional and explicit study of how they might best be implemented prior to
15
16
17 widespread implementation.(1, 2, 5)
18
19

20 The overarching objective of this research program is to improve health outcomes and
21
22 transform the delivery of care for pediatric transplant patients in Canada by integrating
23
24 ePROMs into standard clinical practice. This program of research uses a phased approach to
25
26 target the methodological and practical decisions (e.g., determining which standardized PROMs
27
28 to use, identifying goals for collecting PROMs, selecting patients, setting, and timing of
29
30 assessment, etc.) needed to guide systematic and effective implementation of ePROMs into
31
32 'real-world' pediatric patient care settings.(13) Recently completed foundational research to
33
34 explore these questions within pediatric solid organ transplantation consisted of the three
35
36 phases of work outlined below.
37
38
39
40
41

42 **Phase 1: Systematic review**

43

44 A systematic review was conducted to identify PROMs used in pediatric solid organ
45
46 transplantation.(14) A total of 4,305 studies were identified, of which 62 describing 47 PROMs
47
48 were selected for analysis and were appraised for adherence to internationally recommended
49
50 guidelines for item generation, item reduction, and psychometric properties.(15) Findings
51
52 revealed six standardized PROMs that had undergone psychometric evaluation in a pediatric
53
54
55
56
57
58
59
60

1
2
3 solid organ transplant population. This phase of work identified standardized PROMs to
4
5 consider for implementation into clinical care.
6
7

8 **Phase 2: Interviews with key stakeholders**

9
10 Interviews with key stakeholders across Canada, including: (a) pediatric solid organ
11
12 transplant recipients, (b) parent(s)/caregiver(s), and (c) healthcare providers, were conducted
13
14 to explore perspectives regarding ePROMs implementation into clinical practice.⁽¹⁶⁾ Sixty-three
15
16 participants across five Canadian pediatric transplant centres were interviewed, among whom
17
18 nearly all (60/63; 95%) were supportive of implementing an ePROM system into clinical practice
19
20 with the primary goals of: (1) integrating the transplant patient's overall well-being into the
21
22 clinical care conversation, (2) capturing the patient's voice and increasing patient engagement,
23
24 and (3) informing pediatric transplant clinical care. Insights for effective PROM implementation
25
26 included the remote completion of ePROMs in advance of clinical appointments for patients
27
28 eight to 10 years of age or older.
29
30
31
32
33

34 **Phase 3: Consensus workshop**

35
36 A two-day consensus workshop was hosted in December 2018 in Toronto to further
37
38 explore how ePROMs could best be implemented into pediatric transplant clinical practice.
39
40 Workshop proceedings were informed by the results of Phases 1 and 2. The workshop was
41
42 attended by 25 leading experts in the fields of pediatric solid organ transplantation, PROMs,
43
44 implementation science, and computational medicine, as well as patients, caregivers,
45
46 healthcare providers, researchers, and administrators from across Canada. Workshop outcomes
47
48 included: (1) consensus on key methodological and operational decisions for implementing
49
50 ePROMs into practice (e.g. which standardized PROMS to utilize, the setting and timing of
51
52
53
54
55
56
57
58
59
60

1
2
3 assessment, as well as the mode for administering ePROMs), (2) a research plan to design,
4
5 develop and evaluate the usability and implementation of an ePROM platform, and (3) a
6
7 knowledge translation strategy to disseminate research findings to key knowledge users (e.g.
8
9 newsletter, peer-reviewed publications, website posting, national and international
10
11 presentations). The consensus workshop captured attendees' perspectives on practice and
12
13 systems-based facilitators and barriers to implementing ePROMs and was instrumental in
14
15 ensuring that future research would be relevant and meaningful to stakeholders.
16
17
18

19 20 **Study objectives**

21
22 Results from Phases 1 to 3 inform the current study, Phases 4 and 5.(17) The
23
24 overarching aim of the proposed study, which will be conducted within the Transplant and
25
26 Regenerative Medicine Centre at The Hospital for Sick Children (SickKids), is to create an
27
28 ePROM platform called Voxe, that will capture and implement patient-reported outcomes into
29
30 the clinical care workflow for pediatric organ transplant patients. Specifically, Phase 4 aims to
31
32 design the user interfaces of the Voxe platform, and Phase 5 aims to develop the Voxe software
33
34 and conduct usability testing of Voxe in preparation for a future implementation-effectiveness
35
36 trial (Phase 6). A graphical representation of the different research phases is displayed in Figure
37
38
39
40 *1: Measuring What Matters: Implementing Patient-Reported Outcome Measures into Clinical*
41
42
43
44
45 *Practice – A Research Program.*
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

METHODS

Phase 4: User interface design of Voxe ePROM platform

eHealth technologies designed and developed based on assumptions of end-user motivations, goals or needs, are often less effective than those that engage end-users throughout the process.(10, 18) Thus, a 'user-centric' approach in which end-users (i.e., patients and healthcare providers) are central to the design process will guide the design and development of Voxe. This evidence-based approach will consider the needs of Voxe users at each design phase and will allow for iterative modification of wireframes, which are the static, two-dimensional visual representation or layout of Voxe, to best meet their identified needs.(19-21) A 'user-centric' approach is paramount for user engagement with the platform, ultimately contributing to the effectiveness of the platform itself.(10)

Study participants and inclusion criteria

Purposive sampling will be used to recruit 12 patient participants across age, organ type, sex, gender, and ethnicity from the Transplant and Regenerative Medicine Centre at SickKids to obtain maximum variation.(22) Twelve members of the patients' interdisciplinary healthcare teams at SickKids will also be recruited purposively across professional disciplines, years of practice, sex, gender and ethnicity. This sample size is consistent with testing methods for clinical information systems.(23)

Patients eligible to participate include those who are: (a) 10 to 17 years of age, (b) able to speak and read English, and (c) heart, kidney, liver or lung transplant recipients who are a minimum of three months post-transplant. Patients with significant cognitive impairments, as determined by a healthcare team member, will not be invited to participate. Eligible healthcare

1
2
3 providers include any member of the interdisciplinary healthcare team within the Transplant
4
5 and Regenerative Medicine Centre at SickKids.
6

7 8 Procedures and outcomes 9

10 The design of preliminary Voxe wireframes will be guided by: (1) stakeholder input
11
12 gleaned from previous phases of research,(14, 16) and (2) design workshop processes, including
13
14 identification of Voxe users (i.e., patients and healthcare providers) and the tasks they will
15
16 complete on their respective platforms (i.e., persona and task inventory development).
17

18 Following the design of preliminary wireframes, a rapid and iterative testing methodology will
19
20 be used to evaluate, learn and improve Voxe prior to development (i.e., coding and launch).(19)
21
22

23 Three rounds of testing sessions will be scheduled with patient and healthcare provider
24
25 participants to elicit feedback on Voxe design features. Written consent and assent, as well as
26
27 demographic information, will be obtained prior to study participation.
28
29

30 Each testing session will be conducted virtually via the Personal Health Information
31
32 Protection Act-compliant version of Zoom or Microsoft Teams. During each session,
33
34 International Organization for Standardization key performance indicators, consensus-base
35
36 standards for technology, will be benchmarked and tracked to validate each iteration for
37
38 success.(24, 25) In particular, objective and subjective standards common in user experience
39
40 design testing,(26) will be collected to measure: (1) effectiveness – accuracy and completeness
41
42 with which users achieve specific goals, displayed as a percentage of tasks successfully
43
44 completed by users, and (2) efficiency – resources used in relation to results achieved,
45
46 represented by the time it takes users to successfully complete the task.(27) Prior to the
47
48 scheduled testing session, the URL for the testing website will be emailed to the participant.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 During the session, participants will complete task-based activities using incremental segments
4
5 (i.e., wireframes) of the Voxe platform.
6
7

8 Following the task-based activities, healthcare provider participants will complete a
9
10 Likert scale questionnaire to assess the key performance indicator satisfaction. Patient
11
12 participant's overall impression and experience with the Voxe platform will be evaluated using
13
14 the Microsoft Desirability Toolkit.(28) Patient participants will select five words from a list of
15
16 product reaction words to describe their attitude towards the Voxe platform. Product reaction
17
18 words, such as "fun" and "calm" describe intangible emotional response towards the
19
20 interface.(29)
21
22
23

24
25 Lastly, participants will share their likes and dislikes of the Voxe platform design and
26
27 comment on the platform's ease of use and elements of functionality during a virtual semi-
28
29 structured qualitative interview. Semi-structured interviews foster reciprocity between the
30
31 participant and interviewer, allow the interviewer to ask pertinent follow-up questions to elicit
32
33 rich data and enable the participant to express themselves using their own words.(30-32) The
34
35 interview guide will be developed by the study team and will be informed by clinical knowledge
36
37 and experience. Interviews will be conducted by study team members trained in qualitative
38
39 methods. Sessions will be audio-recorded, transcribed verbatim and de-identified to protect
40
41 participant confidentiality. Recruitment for Phase 4 began in May 2020.
42
43
44
45

46 47 Data analysis 48

49 Data collected during the testing sessions, including objective and subjective
50
51 International Organization for Standardization key performance indicators, will be used to
52
53 refine Voxe. The research team will utilize content and thematic analysis to categorize the data
54
55
56
57
58
59
60

1
2
3 collected during qualitative interviews.(33-35) Two members of the study team experienced in
4
5 qualitative methods, will code the data independently, and categories will be reviewed and
6
7 refined until consensus is reached for emerging themes. Trustworthiness will be achieved by
8
9 facilitating member checking and soliciting rich description during interviews, as well as hosting
10
11 frequent team meetings to support in-depth, iterative analysis with reflexive discussion among
12
13 team members. Analysis will be complete once the research team agrees that thematic
14
15 saturation is attained.(35) NVivo 12 will be used to manage qualitative data.(36) Quantitative
16
17 data collected during the testing sessions will be triangulated with qualitative themes to
18
19 provide a richer understanding of end-users' experience with Voxe. Refinements will be made
20
21 to the Voxe platform design based on the triangulated data. Three rounds of iterative feedback
22
23 testing will be conducted with each participant population (i.e. four participants per round)
24
25 until Voxe is considered acceptable to participating end-users with no further refinements
26
27 identified.(37, 38) Following the third round of patient and healthcare provider iterative testing,
28
29 the design team will share the final Voxe patient and healthcare provider annotated wireframes
30
31 with the development team.

Phase 5: Development of ePROM platform Voxe and usability testing

41
42 Usability is defined as the “extent to which a system, product or service can be used by
43
44 specified users to achieve specified goals with effectiveness, efficiency and satisfaction in a
45
46 specified context of use”.(24) To test Voxe usability, the think-aloud technique will be
47
48 employed in which participants will verbalize their thoughts and feelings while interacting with
49
50 Voxe to complete structured tasks.(39, 40) The think-aloud technique is integral to
51
52 understanding the end-user experience with Voxe and will highlight potential barriers to Voxe
53
54
55
56
57
58
59
60

1
2
3 adoption that can inform its subsequent implementation.(39, 40) Semi-structured interviews
4
5 and data analytics, described below, will also be conducted.(41)
6
7

8 Study participants and inclusion criteria 9

10 Purposive sampling will be used to recruit 12 to 20 patient participants across age,
11
12 organ type, sex, gender, and ethnicity from the Transplant and Regenerative Medicine Centre
13
14 at SickKids. Twelve to 20 members of the patients' interdisciplinary healthcare team will also be
15
16 recruited purposively across professional disciplines, years of practice, sex, gender and
17
18 ethnicity.(23)
19
20
21

22 Patients eligible to participate will include those who are: (a) eight to 17 years of age
23
24 with capacity to assent/consent, (b) those able to speak and read English, (c) heart, kidney, liver
25
26 or lung transplant recipients, and (d) who are a minimum of three months post-transplant.
27
28 Informed consent will be obtained from the parents/legal guardians of participants who
29
30 provide assent. Eligible healthcare providers include any member of the interdisciplinary
31
32 healthcare team within the Transplant and Regenerative Medicine Centre at SickKids who have
33
34 worked within their position for a minimum of six months.
35
36
37
38
39

40 Procedures and outcomes 41

42 Following Phase 4, the development team will use the Voxe patient and healthcare
43
44 provider annotated wireframes to develop the respective interfaces of the Voxe ePROM
45
46 platform, using an agile, scrum framework.(19) A scrum framework is a project management
47
48 process within a hybrid software development model that applies a flexible development
49
50 process and places the needs of system end-users at the forefront to ensure that Voxe is both
51
52 useful and usable.(42, 43) The principles of iterative feedback, incremental development and
53
54
55
56
57
58
59
60

1
2
3 continual stakeholder involvement are central to this dynamic approach.(42, 43) Feature
4
5 development will be phased and will include authentication, user dashboards, account settings,
6
7 privacy/security controls and survey submission/review functionality.
8
9

10 Four rounds of iterative testing will be completed with three to five patients and three
11
12 to five healthcare providers per round, as is consistent with usability testing methods for clinical
13
14 information systems.(23) The first two rounds will be conducted in-person or virtual with a
15
16 member of the study team, using smartphones, tablets and/or computers. Both patient and
17
18 healthcare provider participants will be asked to complete a core set of tasks on Voxe which will
19
20 be presented to them in the form of scenarios that they may encounter while interacting with
21
22 Voxe. For example, patients will be provided with an anonymous username and password,
23
24 invited to successfully log into Voxe, and navigate Voxe to complete available ePROMs (i.e.
25
26 PedsQL™ Generic Core Scales(44)). Healthcare providers will be invited to navigate Voxe to
27
28 view and interpret sample ePROM results. Employing think-aloud methodology, participants
29
30 will be encouraged to voice out loud what they are looking at, thinking, doing and feeling as
31
32 they navigate the platform.(39, 41)
33
34
35
36
37
38
39

40 The last two testing rounds will be conducted to simulate 'real-world' settings.
41
42 An automated text message or email with an embedded hyperlink will be sent to patients
43
44 asking them to access Voxe remotely on a smartphone, tablet or computer. Patients will
45
46 independently log into Voxe using an anonymous username and password and navigate the
47
48 platform to complete available ePROMs. Healthcare providers will be asked to access Voxe on a
49
50 computer and independently navigate the Voxe platform to view and interpret ePROM data
51
52 entered by patients.
53
54
55
56
57
58
59
60

1
2
3 Objective measures to be collected include: (1) time on task – the time it takes to
4 complete each task, (2) successful task completion (fidelity) – when the end-user achieves the
5 end goal of the task, (3) frequency of critical errors – a high severity error that could prevent an
6 end-user from being able to complete a task, (4) frequency of non-critical errors – a low
7 severity error that could decrease the efficiency with which an end-user completes a task, and
8 (5) error-free rate – the percentage of task completions that occurred without any errors.(45,
9
10
11
12
13
14
15
16
17
18 46) Following each testing round, in-person or virtual semi-structured interviews will be
19 conducted to ascertain what participants liked or disliked and why, ease of use, elements of
20 functionality in the context of typical practice workflow, as well as suggestions for
21 improvements. Iterative usability testing will also be conducted until Voxe is considered
22 acceptable to participating end-users with no further refinements identified.(37, 38) Interviews
23 will be audio-recorded, transcribed verbatim and de-identified.
24
25
26
27
28
29
30
31

32 Data analysis

33
34
35 Quantitative data including time on task, successful task completion, frequency of
36 critical and non-critical errors, and error-free rate will be analyzed and descriptive statistics will
37 be produced. Similar to Phase 4, qualitative interviews will be subject to content and thematic
38 analysis to identify emerging themes.(33, 34) Themes will be coded and categorized using
39 NVivo 12 according to type and frequency of occurrence.(36) Quantitative and qualitative data
40 will be triangulated to inform changes made to the Voxe platform.
41
42
43
44
45
46
47
48
49

50 Patient and public involvement

51
52 Phases 4 and 5 are informed by the invaluable feedback provided by stakeholders,
53 including pediatric patients, their caregivers and healthcare providers, from previous phases of
54
55
56
57
58
59
60

1
2
3 research.(16) Patients' and healthcare providers' thoughts, feelings and perspectives about
4
5 Voxe captured through research processes described in this protocol will continue to guide this
6
7 research program. Stakeholder involvement will ensure the implementation of evidence-based
8
9 interventions integral to achieving meaningful patient outcomes.
10
11

12 **ETHICS AND DISSEMINATION**

13 **Ethics approval and consent to participate**

14
15
16 Institutional research ethics board approval has been provided by SickKids (REB number:
17
18 1000057043 (Phase 4); REB number: 1000067700 (Phase 5)). All participants will provide
19
20 informed consent or assent prior to their involvement in the study. For participants who
21
22 provide informed assent, informed consent will be obtained from the parents/legal guardians
23
24 prior to study participation.
25
26
27
28
29

30 **Information security**

31
32 All interviews will be audio recorded and transcribed verbatim. Transcription will be completed
33
34 by a member of the study team. All transcriptions will be de-identified to protect participant
35
36 confidentiality. All identifying information, both paper copy and electronic information, will be
37
38 kept confidential. Use of data over the course of the study and dissemination of results will
39
40 follow standard practice guidelines as determined by the SickKids Research Institute.
41
42
43
44

45 **Discussion and dissemination**

46
47 The collection of PROMs provides the opportunity to incorporate patient-centred
48
49 perspectives into pediatric clinical practice.(2, 6, 11, 47-50) The creation of the Voxe ePROM
50
51 platform will reform the practice of pediatric medicine by enhancing the capacity of patient-
52
53 provider partnerships to identify and address issues that are most meaningful to patients.(51)
54
55
56
57
58
59
60

1
2
3 The design and development of Voxe outlined in this protocol are critical to answering
4
5 important methodological and operational questions that will inform the implementation of
6
7 ePROMs in pediatric clinical settings.
8
9

10 Engaging patients and healthcare providers throughout Voxe design and development
11
12 will result in the creation and launch of a user-centred ePROM platform. For patients, Voxe will
13
14 facilitate ePROM data collection in a child friendly and patient-centred manner. For healthcare
15
16 providers, Voxe will facilitate convenient and timely review of patient ePROM data,
17
18 collaboration within healthcare teams, and shared decision-making discussions between
19
20 healthcare providers and patients during clinical encounters.
21
22
23
24

25 During Phase 4, patients and healthcare providers will share their likes and dislikes of
26
27 the design and comment on Voxe functionality and ease of use. It is critical that Voxe design
28
29 iterations integrate this feedback, as the interface needs to be designed in a way that is logical,
30
31 intuitive, and user friendly for end-users. This process will ensure that there is an evidence-
32
33 based iterative design in place before usability testing. In Phase 5, patients and healthcare
34
35 providers will comment on what they liked or disliked about Voxe and why, Voxe ease of use,
36
37 and elements of functionality in the context of typical practice workflow, as well as suggestions
38
39 to improve Voxe. Voxe will be further refined according to this feedback until a final version is
40
41 produced. The final product will enhance the experience of end-users with systematically
42
43 tested functionality and design. Following the procedures outlined above, creating an evidence-
44
45 based ePROM platform will enable these outcomes. Findings from this study will be widely
46
47 disseminated through infographics, posts on the research team's website, peer-reviewed
48
49 journal publications and presentations at patient and family educational events as well as
50
51
52
53
54
55
56
57
58
59
60

1
2
3 scientific and academic conferences. Data collection is expected to be completed by the end of
4
5
6 2021 with publication of results in early 2022.

7
8 This research lays the groundwork for future investigations that will include Voxe
9
10 healthcare provider orientation and competency training as part of a more comprehensive
11
12 implementation plan. Additionally, an implementation-effectiveness evaluation (Phase 6) of the
13
14 Voxe ePROM platform will be conducted to explore how Voxe can be effectively implemented
15
16
17 in a manner that impacts pediatric transplantation patient's health outcomes and clinical care.
18
19

20 **List of abbreviations**

21 ePROM – Electronic patient-reported outcome measure

22 PROM – Patient-reported outcome measure
23
24

25 ***Figure Caption***

26 Figure 1: Measuring What Matters: Implementing Patient-Reported Outcome Measures into
27 Clinical Practice – A Research Program
28
29

30 ***Acknowledgements***

31 The authors thank our patient partners and past and future research participants.
32
33

34 ***Competing interests***

35 The authors declare that they have no competing interests.
36
37

38 ***Funding***

39 This study was supported by the SickKids Transplant and Regenerative Medicine Centre and
40 Astellas Pilot Grant (Grant/Award Number: Not Applicable), the Canadian Donation and
41 Transplantation Research Program Innovation Grant (Grant/Award Number: Not Applicable)
42 and the Health Canada Health Care Policy Contribution Program (Grant/Award Number: 1920-
43 HQ-000105).
44
45

46 ***Authors' contributions***

47 All authors (SJA, SJP, JL, MBa, MBr, DM, RSP, AS, JS) contributed to project conception and
48 study design. SJA, SJP and JL drafted the manuscript. All authors (SJA, SJP, JL, MBa, MBr, DM,
49 RSP, AS, JS) read the manuscript and gave final approval of the version to be published.
50
51
52
53
54
55
56
57
58
59
60

References

1. Rossano JW, Cherikh WS, Chambers DC, Goldfarb S, Hayes D, Khush KK, et al. The international thoracic organ transplant registry of the International Society for Heart and Lung Transplantation: Twenty-first pediatric heart transplantation report—2018; Focus theme: Multiorgan transplantation. *J Heart Lung Transplant*. 2018;37(10):1184-95.
2. Bevans KB, Moon J, Carle AC, Mara CA, Lai J-S, DiMarco L, et al. Patient reported outcomes as indicators of pediatric health care quality. *Acad Pediatr*. 2014;14(5):S90-S6.
3. US Department of Health Human Services Food and Drug Administration. Guidance for industry - Patient-reported outcome measures: Use in medical product development to support labeling claims. *Fed Reg*. 2009;74(235):65132-3.
4. Santana M-J, Feeny D. Framework to assess the effects of using patient-reported outcome measures in chronic care management. *Qual Life Res*. 2014;23(5):1505-13.
5. Fung CH, Hays RD. Prospects and challenges in using patient-reported outcomes in clinical practice. *Qual Life Res*. 2008;17(10):1297-302.
6. Bitton A, Onega T, Tosteson AN, Haas JS. Toward a better understanding of patient-reported outcomes in clinical practice. *Am J Manag Care*. 2014;20(4):281.
7. Nelson EC, Eftimovska E, Lind C, Hager A, Wasson JH, Lindblad S. Patient reported outcome measures in practice. *BMJ*. 2015;350.
8. Valderas J, Kotzeva A, Espallargues M, Guyatt G, Ferrans C, Halyard M, et al. The impact of measuring patient-reported outcomes in clinical practice: A systematic review of the literature. *Qual Life Res*. 2008;17(2):179-93.
9. Forrest CB. Digitization of patient-reported outcomes. *Value Health*. 2013;16(4):459-60.
10. McCurdie T, Taneva S, Casselman M, Yeung M, McDaniel C, Ho W, et al. mHealth consumer apps: The case for user-centered design. *Biomed Instrum Technol*. 2012;46(Suppl 2):49-56.
11. Huang I-C, Revicki DA, Schwartz CE. *Measuring pediatric patient-reported outcomes: Good progress but a long way to go*. Springer; 2014.
12. Hoffmann T, Bennett S, Del Mar C. *Evidence-based practice across the health professions-e-book*: Elsevier Health Sciences; 2013.
13. Aaronson N, Elliott T, Greenhalgh J, Halyard M, Hess R, Miller D, et al. *User's guide to implementing patient-reported outcomes assessment in clinical practice version 2*. 2015.
14. Anthony SJ, Stinson H, Lazor T, Young K, Hundert A, Santana MJ, et al. Patient-reported outcome measures within pediatric solid organ transplantation: A systematic review. *Pediatr Transplant*. 2019;23(6):e13518.
15. Terwee CB, Mokkink LB, Knol DL, Ostelo RW, Bouter LM, de Vet HC. Rating the methodological quality in systematic reviews of studies on measurement properties: A scoring system for the COSMIN checklist. *Qual Life Res*. 2012;21(4):651-7.
16. Anthony SJ, Young K, Pol SJ, Selkirk EK, Blydt-Hansen T, Boucher S, et al. Patient-reported outcome measures in pediatric solid organ transplantation: Exploring stakeholder perspectives on clinical implementation through qualitative description. *Qual Life Res*. 2021.
17. Meyers DC, Durlak JA, Wandersman A. The quality implementation framework: A synthesis of critical steps in the implementation process. *Am J Community Psychol*. 2012;50(3-4):462-80.

18. Verhoeven F, Tanja-Dijkstra K, Nijland N, Eysenbach G, van Gemert-Pijnen L. Asynchronous and synchronous teleconsultation for diabetes care: A systematic literature review. *J Diabetes Sci Technol*. 2010;4(3):666-84.
19. Barnum CM. Chapter 1: Establishing the essentials. In: Merken S, editor. *Usability testing essentials: ready, set test!* 2 ed. Amsterdam: Elsevier; 2020. p. 9-33.
20. US General Services Administration Technology Transformation Services. *Wireframing 2021* [Available from: <https://www.usability.gov/how-to-and-tools/methods/wireframing.html>].
21. ProductPlan. *Wireframe 2021* [Available from: <https://www.productplan.com/glossary/wireframe/>].
22. Palinkas LA, Horwitz SM, Green CA, Wisdom JP, Duan N, Hoagwood K. Purposeful sampling for qualitative data collection and analysis in mixed method implementation research. *Adm Policy Ment Health*. 2015;42(5):533-44.
23. Kushniruk AW, Patel VL. Cognitive and usability engineering methods for the evaluation of clinical information systems. *J Biomed Inform*. 2004;37(1):56-76.
24. International Organization for Standardization. *ISO 9241-11:2018(en) Ergonomics of human-system interaction — Part 11: Usability: Definitions and concepts 2018* [Available from: <https://www.iso.org/obp/ui/#iso:std:iso:9241:-11:ed-2:v1:en>].
25. International Organization for Standardization. *About us: What we do* [Available from: <https://www.iso.org/what-we-do.html>].
26. Barnum CM. Chapter 8: Analyzing the findings. In: Merken S, editor. *Usability testing essentials: ready, set test!* 2 ed. Amsterdam: Elsevier; 2020. p. 287-319.
27. International Organization for Standardization. *ISO 9000:2015(en) Quality management systems — Fundamentals and vocabulary 2015* [Available from: <https://www.iso.org/obp/ui/#iso:std:iso:9000:ed-4:v1:en>].
28. Barnum C. Chapter 6: Preparing for usability testing. In: Merken S, editor. *Usability testing essentials: ready, set test!* 2 ed. Amsterdam: Elsevier; 2020. p. 197-248.
29. Benedek J, Miner T. Measuring desirability: New methods for evaluating desirability in a usability lab setting. *Usability Professionals Association*. 2002;2003(8-12):57.
30. Galletta A. *Mastering the semi-structured interview and beyond: From research design to analysis and publication*: NYU Press; 2013.
31. Rubin HJ, Rubin IS. *Qualitative interviewing: The art of hearing the data*. 2 ed. Thousand Oaks, CA: SAGE; 2005.
32. Kallio H, Pietilä AM, Johnson M, Kangasniemi M. Systematic methodological review: Developing a framework for a qualitative semi-structured interview guide. *J Adv Nurs*. 2016;72(12):2954-65.
33. Gibbs G. *Analysing qualitative data*. London, England: SAGE; 2007.
34. Fereday J, Muir-Cochrane E. Demonstrating rigor using thematic analysis: A hybrid approach of inductive and deductive coding and theme development. *Int J Qual Methods*. 2006;5(1):80-92.
35. Elo S, Kyngäs H. The qualitative content analysis process. *J Adv Nurs*. 2008;62(1):107-15.
36. Richards L. *Using NVivo in qualitative research*: Sage; 1999.
37. Stinson JN, Jibb LA, Nguyen C, Nathan PC, Maloney AM, Dupuis LL, et al. Development and testing of a multidimensional iPhone pain assessment application for adolescents with cancer. *J Med Internet Res*. 2013;15(3):e51.

- 1
2
3 38. Macefield R. How to specify the participant group size for usability studies: A
4 practitioner's guide. *J Usability Stud.* 2009;5(1):34-45.
- 5 39. Li AC, Kannry JL, Kushniruk A, Chrimes D, McGinn TG, Edonyabo D, et al. Integrating
6 usability testing and think-aloud protocol analysis with “near-live” clinical simulations in
7 evaluating clinical decision support. *Int J Med Inform.* 2012;81(11):761-72.
- 8 40. Rose AF, Schnipper JL, Park ER, Poon EG, Li Q, Middleton B. Using qualitative studies to
9 improve the usability of an EMR. *J Biomed Inform.* 2005;38(1):51-60.
- 10 41. Lewis C. Using the “think aloud” method in cognitive interface design. New York: IBM.
11 1982.
- 12 42. Cervone F. Understanding agile project management methods using scrum. *OCLC*
13 *Systems & Services International digital library perspectives.* 2011;1(27):18-22.
- 14 43. Brhel AM, H; Maedche, A; Werder, K. Exploring principles of user-centred agile software
15 development: A literature review. *Information and Software Technology.* 2015(61):163-81.
- 16 44. Varni J, Seid M, Kurtin P. PedsQL TM 4.0: Reliability and validity of the Pediatric Quality
17 of Life Inventory TM Version 4.0 Generic Core Scales in healthy and patient populations. *Med*
18 *Care.* 2001;39:800-12.
- 19 45. US General Services Administration Technology Transformation Services. Planning a
20 Usability Test 2021 [Available from: [https://www.usability.gov/how-to-and-](https://www.usability.gov/how-to-and-tools/methods/planning-usability-testing.html)
21 [tools/methods/planning-usability-testing.html](https://www.usability.gov/how-to-and-tools/methods/planning-usability-testing.html)].
- 22 46. Tullis TA, Bill. Chapter 4 – Performance Metrics. *Measuring the User Experience.* Second
23 ed: Elsevier; 2013. p. 63–97.
- 24 47. Calvert M, Kyte D, Price G, Valderas JM, Hjollund NH. Maximising the impact of patient
25 reported outcome assessment for patients and society. *BMJ.* 2019;364.
- 26 48. Haverman L, Engelen V, van Rossum MA, Heymans HS, Grootenhuis MA. Monitoring
27 health-related quality of life in paediatric practice: Development of an innovative web-based
28 application. *BMC Pediatr.* 2011;11(1):1-7.
- 29 49. Haywood K, Brett J, Salek S, Marlett N, Penman C, Shklarov S, et al. Patient and public
30 engagement in health-related quality of life and patient-reported outcomes research: What is
31 important and why should we care? Findings from the first ISOQOL patient engagement
32 symposium. *Qual Life Res.* 2015;24(5):1069-76.
- 33 50. Cleemput I, Dobbels F. Measuring patient-reported outcomes in solid organ transplant
34 recipients. *Pharmacoeconomics.* 2007;25(4):269-86.
- 35 51. Engelen V, Detmar S, Koopman H, Maurice-Stam H, Caron H, Hoogerbrugge P, et al.
36 Reporting health-related quality of life scores to physicians during routine follow-up visits of
37 pediatric oncology patients: Is it effective? *Pediatr Blood Cancer.* 2012;58(5):766-74.
- 38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1: Measuring What Matters: Implementing Patient-Reported Outcome Measures into Clinical Practice – A Research Program

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47



For peer review only

GUIDED – a guideline for reporting for intervention development studies.

Supplementary File 1: Blank Checklist

Item description	Explanation	Page in manuscript where item is located	Other*
1. Report the context for which the intervention was developed.	Understanding the context in which an intervention was developed informs readers about the suitability and transferability of the intervention to the context in which they are considering evaluating, adapting or using the intervention. Context here can include place, organisational and wider socio-political factors that may influence the development and/or delivery of the intervention (15).	9, 10, 13, 14	
2. Report the purpose of the intervention development process.	Clearly describing the purpose of the intervention specifies what it sets out to achieve. The purpose may be informed by research priorities, for example those identified in systematic reviews, evidence gaps set out in practice guidance such as The National Institute for Health and Care Excellence or specific prioritisation exercises such as those undertaken with patients and practitioners through the James Lind Alliance.	8	
3. Report the target population for the intervention development process.	The target population is the population that will potentially benefit from the intervention – this may include patients, clinicians, and/or members of the public. If the target population is clearly described then readers will be able to understand the relevance of the intervention to their own research or practice. Health inequalities, gender and ethnicity are features of the target population that may be relevant to intervention development processes.	9, 10, 13, 14	
4. Report how any published intervention development approach contributed to the development process	Many formal intervention development approaches exist and are used to guide the intervention development process (e.g. 6Squid (16) or The Person Based Approach to Intervention Development (17)). Where a formal intervention development approach is used, it is helpful to describe the process that was followed, including any deviations. More general approaches to intervention development also exist and have been categorised as follows (3):- Target Population-centred intervention development; evidence and theory-based intervention development; partnership intervention development; implementation-based intervention development; efficacy-based intervention development; step or phased-based intervention development; and intervention-specific intervention development (3). These approaches do not always have specific guidance that describe their use. Nevertheless, it is helpful to give a rich description of how any published approach was operationalised	9, 13, 14	
5. Report how evidence from different sources informed the intervention development process.	Intervention development is often based on published evidence and/or primary data that has been collected to inform the intervention development process. It is useful to describe and reference all forms of evidence and data that have informed the development of the intervention because evidence bases can change rapidly, and to explain the manner in which the evidence and/or data was used. Understanding what evidence was and was not available at the time of intervention development can help readers to assess transferability to their current situation.	6-8	
6. Report how/if published theory informed the intervention development process.	Reporting whether and how theory informed the intervention development process aids the reader's understanding of the theoretical rationale that underpins the intervention. Though not mentioned in the e-Delphi or consensus meeting, it became increasingly apparent through the development of our guidance that this theory item could relate to either existing published theory or programme theory	5, 6, 9, 13, 14	
7. Report any use of components from an existing intervention in the current intervention development process.	Some interventions are developed with components that have been adopted from existing interventions. Clearly identifying components that have been adopted or adapted and acknowledging their original source helps the reader to understand and distinguish between the novel and adopted components of the new intervention.	5, 6	
8. Report any guiding principles, people or factors that were prioritised when making decisions during the intervention development process.	Reporting any guiding principles that governed the development of the application helps the reader to understand the authors' reasoning behind the decisions that were made. These could include the examples of particular populations who views are being considered when designing the intervention, the modality that is viewed as being most appropriate, design features considered important for the target population, or the potential for the intervention to be scaled up.	5-8	

Item description	Explanation	Page in manuscript where item is located	Other*
9. Report how stakeholders contributed to the intervention development process.	Potential stakeholders can include patient and community representatives, local and national policy makers, health care providers and those paying for or commissioning health care. Each of these groups may influence the intervention development process in different ways. Specifying how differing groups of stakeholders contributed to the intervention development process helps the reader to understand how stakeholders were involved and the degree of influence they had on the overall process. Further detail on how to integrate stakeholder contributions within intervention reporting are available (19).	6-11, 13-15	
10. Report how the intervention changed in content and format from the start of the intervention development process.	Intervention development is frequently an iterative process. The conclusion of the initial phase of intervention development does not necessarily mean that all uncertainties have been addressed. It is helpful to list remaining uncertainties such as the intervention intensity, mode of delivery, materials, procedures, or type of location that the intervention is most suitable for. This can guide other researchers to potential future areas of research and practitioners about uncertainties relevant to their healthcare context.	N/A	
11. Report any changes to interventions required or likely to be required for subgroups.	Specifying any changes that the intervention development team perceive are required for the intervention to be delivered or tailored to specific sub groups enables readers to understand the applicability of the intervention to their target population or context. These changes could include changes to personnel delivering the intervention, to the content of the intervention, or to the mode of delivery of the intervention.	N/A	
12. Report important uncertainties at the end of the intervention development process.	Intervention development is frequently an iterative process. The conclusion of the initial phase of intervention development does not necessarily mean that all uncertainties have been addressed. It is helpful to list remaining uncertainties such as the intervention intensity, mode of delivery, materials, procedures, or type of location that the intervention is most suitable for. This can guide other researchers to potential future areas of research and practitioners about uncertainties relevant to their healthcare context.	N/A	
13. Follow TIDieR guidance when describing the developed intervention.	Interventions have been poorly reported for a number of years. In response to this, internationally recognized guidance has been published to support the high quality reporting of health care? interventions ⁵ and public health interventions ¹⁴ . This guidance should therefore be followed when describing a developed intervention.	N/A	
14. Report the intervention development process in an open access format.	Unless reports of intervention development are available people considering using an intervention cannot understand the process that was undertaken and make a judgement about its appropriateness to their context. It also limits cumulative learning about intervention development methodology and observed consequences at later evaluation, translation and implementation stages. Reporting intervention development in an open access (Gold or Green) publishing format increases the accessibility and visibility of intervention development research and makes it more likely to be read and used. Potential platforms for open access publication of intervention development include open access journal publications, freely accessible funder reports or a study web-page that details the intervention development process.	N/A	

*e.g. if item is reported elsewhere, then the location of this information can be stated here.

BMJ Open

The creation of an electronic patient-reported outcome measure platform Voxe: A mixed methods study protocol in pediatric solid organ transplantation

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-053119.R2
Article Type:	Protocol
Date Submitted by the Author:	27-Sep-2021
Complete List of Authors:	Anthony, Samantha; The Hospital for Sick Children, Child Health Evaluative Sciences; University of Toronto, Factor-Inwentash Faculty of Social Work Pol, Sarah; The Hospital for Sick Children, Child Health Evaluative Sciences Lin, Jia; The Hospital for Sick Children, Child Health Evaluative Sciences Barwick, Melanie; The Hospital for Sick Children, Child Health Evaluative Sciences; University of Toronto, Dalla Lana School of Public Health Brudno, Michael; University Health Network, Data Aggregation, Translation and Architecture; University of Toronto, Faculty of Arts and Science Manase, Dorin; University Health Network, Data Aggregation, Translation and Architecture Parekh, Rulan; The Hospital for Sick Children, Child Health Evaluative Sciences; The Hospital for Sick Children, Transplant and Regenerative Medicine Centre Silva, Amanda; University Health Network, Data Aggregation, Translation and Architecture Stinson, Jennifer; The Hospital for Sick Children, Child Health Evaluative Sciences; University of Toronto, Lawrence S. Bloomberg Faculty of Nursing
Primary Subject Heading:	Paediatrics
Secondary Subject Heading:	Mental health, Health services research, Patient-centred medicine, Qualitative research, Research methods
Keywords:	Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Transplant medicine < INTERNAL MEDICINE, MENTAL HEALTH, PAEDIATRICS, Paediatric transplant surgery < PAEDIATRIC SURGERY, QUALITATIVE RESEARCH

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Title

The creation of an electronic patient-reported outcome measure platform Voxe: A mixed methods study protocol in pediatric solid organ transplantation

Authors

Samantha J. Anthony¹⁻⁴, Sarah J. Pol¹, Jia Lin¹, Melanie Barwick^{1,5,6}, Michael Brudno^{7,8}, Dorin Manase⁷, Rulan S. Parekh^{1,2,9,10}, Amanda Silva⁷, Jennifer Stinson^{1,11}

1. Child Health Evaluative Sciences, Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, Toronto, ON, Canada
2. Transplant and Regenerative Medicine Centre, The Hospital for Sick Children, Toronto, ON, Canada
3. Factor-Inwentash Faculty of Social Work, University of Toronto, Toronto, ON, Canada
4. Canadian Donation and Transplantation Research Program, Edmonton, AB, Canada
5. Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
6. Temerty Faculty of Medicine, Department of Psychiatry, University of Toronto, Toronto, ON, Canada
7. Data Aggregation, Translation and Architecture, University Health Network, Toronto, ON, Canada
8. Faculty of Arts and Science, Department of Computer Science, University of Toronto, Toronto, ON, Canada
9. Division of Nephrology, The Hospital for Sick Children, Toronto, ON, Canada
10. Division of Nephrology, University Health Network, Toronto, ON, Canada
11. Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON, Canada

Author	ORCID
Samantha J. Anthony	0000-0002-1800-2333
Sarah J. Pol	0000-0003-1883-1753
Jia Lin	0000-0002-8691-3358
Melanie Barwick	0000-0002-2478-604X
Michael Brudno	0000-0001-7947-2243
Rulan S. Parekh	0000-0001-6313-5752
Jennifer Stinson	0000-0002-9969-8052

Corresponding author

Samantha J. Anthony
 The Hospital for Sick Children
 686 Bay Street, Toronto, Ontario, M5G 0A4
 E-mail: samantha.anthony@sickkids.ca

Word count: 3506

Abstract

Introduction:

Patient-reported outcome measures (PROMs) provide an opportunity for meaningful patient engagement and shared decision-making. The objective of this research program is to improve health outcomes for pediatric solid organ transplant patients by implementing PROMs into clinical care. The current study aims to create Voxe, a pediatric user-centred electronic PROM platform, by engaging patients and healthcare providers throughout the design and development process.

Methods and analysis:

The creation of Voxe will occur over two phases that build on previous research. The user interface design phase employs a 'user-centric' approach to identify end-users' needs and iteratively refine the look and layout of Voxe to meet these needs. Transplant recipients, aged 10 to 17, and healthcare providers will participate in three rounds of testing (24 participants total). Participants will: (1) complete task-based activities (outcomes – effectiveness and efficiency), (2) complete questionnaires (outcome – satisfaction), and (3) participate in a semi-structured interview. The following phase involves software development and Voxe usability testing. Transplant recipients, aged eight to 17, and healthcare providers will participate in four rounds of iterative testing (24 to 40 participants total). The think-aloud technique will be employed, and participants will describe their thoughts and feelings while interacting with a Voxe prototype. Participants will: (1) log into Voxe and complete tasks (outcomes – time on task, successful task completion, frequency of critical and non-critical errors and error-free rate), (2) complete questionnaires (outcome – satisfaction), and (3) participate in a semi-

1
2
3 structured interview. Findings will result in the creation and launch of a user-centred electronic
4
5 PROM platform.
6

7 **Ethics and dissemination:**

8
9
10 Research ethics board approval has been provided by The Hospital for Sick Children. This
11
12 research is critical to answering methodological and operational questions to inform Voxe
13
14 implementation in pediatric clinical settings and facilitate PROM data collection. Future
15
16 investigations will include an implementation-effectiveness evaluation.
17
18
19
20
21
22

23 **Article Summary – Strengths and limitations of this study**

- 24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- By engaging pediatric patients and healthcare providers throughout the design and development process, this study will facilitate the creation and launch of an evidence-based pediatric user-centred electronic PROM platform prototype called Voxe
 - A 'user-centric' approach will consider the needs of pediatric patients and healthcare providers at each design phase and allow for iterative modification of wireframes to best meet their identified needs.
 - The think-aloud technique will facilitate understanding of the end-user's experience with Voxe by enabling participants to verbalize their thoughts and feelings while interacting with Voxe to complete specific tasks.
 - As the ability to speak and read English is a requirement for study participation, the perspectives of those who are not able to speak and read English will be missed in these phases of the study.

- This study builds the foundation for future phases of research which will include healthcare provider Voxe orientation and competency training and an implementation-effectiveness evaluation.

Keywords

- Quality in health care
- Transplant medicine
- Mental health
- Paediatrics
- Paediatric transplant surgery
- Qualitative research

BACKGROUND

For children with end-stage organ failure, transplantation is a life-saving therapy.(1, 2) However, evaluating the success of solid organ transplantation based solely on objective clinical outcomes is insufficient. The patient's subjective assessment is a crucial component in evaluating the burden of disease and can be captured via patient-reported outcome measures (PROMs).(1, 2) PROMs are defined as: "any report of the patient's health condition that comes directly from the patient, without interpretation of the patient's response by a clinician or anyone else" (pg. 2).(3) PROMs can capture a patient's self-assessment of functional status, symptoms, treatment adherence, and multiple domains of well-being and quality of life.(4, 5) In doing so, PROMs give patients a voice in their healthcare and provide an opportunity for meaningful engagement.(6) Research indicates that the systematic collection of PROM data enhances patient-clinician communication and shared decision-making, thereby improving health outcomes.(4, 5, 7, 8) The inclusion of PROMs in clinical care assists in identifying valuable information about the impact of transplantation on patients' symptoms as well as their functional and emotional status. This in turn may help healthcare providers to detect under- and unrecognized problems (e.g., depression, anxiety), resulting in more effective patient care (e.g., initiation of clinical interventions) and an efficient healthcare system.

Innovative opportunities to integrate PROMs into clinical practice have been buoyed by recent advances in eHealth.(9, 10) In particular, the development and implementation of electronic PROMs (ePROMs) can help identify important, patient-valued concerns at the point of care, supporting the delivery of appropriate and timely interventions. Moreover, current platforms that support the use of ePROMs are underdeveloped and require better

1
2
3 implementation with clinical care.(2, 6, 7) Further, research on the implementation
4
5 effectiveness of ePROMs in pediatric clinical settings is limited,(2, 11) giving rise to concerns
6
7 that ePROMs may languish, unused, and fail to realize meaningful outcomes for patients.
8
9
10 Implementation of evidence-based interventions is important to ensure meaningful patient
11
12 outcomes.(12) Achieving optimal clinical and health system outcomes for ePROMS will require
13
14 more intentional and explicit study of how they might best be implemented prior to
15
16
17 widespread implementation.(1, 2, 5)

18
19
20 The overarching objective of this research program is to improve health outcomes and
21
22 transform the delivery of care for pediatric transplant patients in Canada by integrating
23
24 ePROMs into standard clinical practice. This program of research uses a phased approach to
25
26 target the methodological and practical decisions (e.g., determining which standardized PROMs
27
28 to use, identifying goals for collecting PROMs, selecting patients, setting, and timing of
29
30 assessment, etc.) needed to guide systematic and effective implementation of ePROMs into
31
32 'real-world' pediatric patient care settings.(13) Recently completed foundational research to
33
34 explore these questions within pediatric solid organ transplantation consisted of the three
35
36 phases of work outlined below.
37
38
39
40

41 42 **Phase 1: Systematic review**

43
44 A systematic review was conducted to identify PROMs used in pediatric solid organ
45
46 transplantation.(14) A total of 4,305 studies were identified, of which 62 describing 47 PROMs
47
48 were selected for analysis and were appraised for adherence to internationally recommended
49
50 guidelines for item generation, item reduction, and psychometric properties.(15) Findings
51
52 revealed six standardized PROMs that had undergone psychometric evaluation in a pediatric
53
54
55
56
57
58
59
60

1
2
3 solid organ transplant population. This phase of work identified standardized PROMs to
4
5 consider for implementation into clinical care.
6
7

8 **Phase 2: Interviews with key stakeholders**

9
10 Interviews with key stakeholders across Canada, including: (a) pediatric solid organ
11
12 transplant recipients, (b) parent(s)/caregiver(s), and (c) healthcare providers, were conducted
13
14 to explore perspectives regarding ePROMs implementation into clinical practice.⁽¹⁶⁾ Sixty-three
15
16 participants across five Canadian pediatric transplant centres were interviewed, among whom
17
18 nearly all (60/63; 95%) were supportive of implementing an ePROM system into clinical practice
19
20 with the primary goals of: (1) integrating the transplant patient's overall well-being into the
21
22 clinical care conversation, (2) capturing the patient's voice and increasing patient engagement,
23
24 and (3) informing pediatric transplant clinical care. Insights for effective PROM implementation
25
26 included the remote completion of ePROMs in advance of clinical appointments for patients
27
28 eight to 10 years of age or older.
29
30
31
32
33

34 **Phase 3: Consensus workshop**

35
36 A two-day consensus workshop was hosted in December 2018 in Toronto to further
37
38 explore how ePROMs could best be implemented into pediatric transplant clinical practice.
39
40 Workshop proceedings were informed by the results of Phases 1 and 2. The workshop was
41
42 attended by 25 leading experts in the fields of pediatric solid organ transplantation, PROMs,
43
44 implementation science, and computational medicine, as well as patients, caregivers,
45
46 healthcare providers, researchers, and administrators from across Canada. Workshop outcomes
47
48 included: (1) consensus on key methodological and operational decisions for implementing
49
50 ePROMs into practice (e.g. which standardized PROMS to utilize, the setting and timing of
51
52
53
54
55
56
57
58
59
60

1
2
3 assessment, as well as the mode for administering ePROMs), (2) a research plan to design,
4
5 develop and evaluate the usability and implementation of an ePROM platform, and (3) a
6
7 knowledge translation strategy to disseminate research findings to key knowledge users (e.g.
8
9 newsletter, peer-reviewed publications, website posting, national and international
10
11 presentations). The consensus workshop captured attendees' perspectives on practice and
12
13 systems-based facilitators and barriers to implementing ePROMs and was instrumental in
14
15 ensuring that future research would be relevant and meaningful to stakeholders.
16
17
18

19 20 **Study objectives**

21
22 Results from Phases 1 to 3 inform the current study, Phases 4 and 5.(17) The
23
24 overarching aim of the proposed study, which will be conducted within the Transplant and
25
26 Regenerative Medicine Centre at The Hospital for Sick Children (SickKids), is to create an
27
28 ePROM platform called Voxe, that will capture and implement patient-reported outcomes into
29
30 the clinical care workflow for pediatric organ transplant patients. Specifically, Phase 4 aims to
31
32 design the user interfaces of the Voxe platform, and Phase 5 aims to develop the Voxe software
33
34 and conduct usability testing of Voxe in preparation for a future implementation-effectiveness
35
36 trial (Phase 6). A graphical representation of the different research phases is displayed in Figure
37
38
39
40 *1: Measuring What Matters: Implementing Patient-Reported Outcome Measures into Clinical*
41
42
43
44
45 *Practice – A Research Program.*
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

METHODS

Phase 4: User interface design of Voxe ePROM platform

eHealth technologies designed and developed based on assumptions of end-user motivations, goals or needs, are often less effective than those that engage end-users throughout the process.(10, 18) Thus, a 'user-centric' approach in which end-users (i.e., patients and healthcare providers) are central to the design process will guide the design and development of Voxe. This evidence-based approach will consider the needs of Voxe users at each design phase and will allow for iterative modification of wireframes, which are the static, two-dimensional visual representation or layout of Voxe, to best meet their identified needs.(19-21) A 'user-centric' approach is paramount for user engagement with the platform, ultimately contributing to the effectiveness of the platform itself.(10)

Study participants and inclusion criteria

Purposive sampling will be used to recruit 12 patient participants across age, organ type, sex, gender, and ethnicity from the Transplant and Regenerative Medicine Centre at SickKids to obtain maximum variation.(22) Twelve members of the patients' interdisciplinary healthcare teams at SickKids will also be recruited purposively across professional disciplines, years of practice, sex, gender and ethnicity. This sample size is consistent with testing methods for clinical information systems.(23)

Patients eligible to participate include those who are: (a) 10 to 17 years of age, (b) able to speak and read English, and (c) heart, kidney, liver or lung transplant recipients who are a minimum of three months post-transplant. Patients with significant cognitive impairments, as determined by a healthcare team member, will not be invited to participate. Eligible healthcare

1
2
3 providers include any member of the interdisciplinary healthcare team within the Transplant
4
5 and Regenerative Medicine Centre at SickKids.
6

7 8 Procedures and outcomes 9

10 The design of preliminary Voxe wireframes will be guided by: (1) stakeholder input
11
12 gleaned from previous phases of research,(14, 16) and (2) design workshop processes, including
13
14 identification of Voxe users (i.e., patients and healthcare providers) and the tasks they will
15
16 complete on their respective platforms (i.e., persona and task inventory development).
17

18 Following the design of preliminary wireframes, a rapid and iterative testing methodology will
19
20 be used to evaluate, learn and improve Voxe prior to development (i.e., coding and launch).(19)
21
22

23 Three rounds of testing sessions will be scheduled with patient and healthcare provider
24
25 participants to elicit feedback on Voxe design features. Written consent and assent, as well as
26
27 demographic information, will be obtained prior to study participation.
28
29

30 Each testing session will be conducted virtually via the Personal Health Information
31
32 Protection Act-compliant version of Zoom or Microsoft Teams. During each session,
33
34 International Organization for Standardization key performance indicators, consensus-base
35
36 standards for technology, will be benchmarked and tracked to validate each iteration for
37
38 success.(24, 25) In particular, objective and subjective standards common in user experience
39
40 design testing,(26) will be collected to measure: (1) effectiveness – accuracy and completeness
41
42 with which users achieve specific goals, displayed as a percentage of tasks successfully
43
44 completed (average task completion rate is 78%; above average is considered successful task
45
46 completion(27, 28)), and (2) efficiency – resources used in relation to results achieved,
47
48 represented by the time it takes users to successfully complete the task.(29) Prior to the
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 scheduled testing session, the URL for the testing website will be emailed to the participant.

4
5 During the session, participants will complete task-based activities using incremental segments
6
7 (i.e., wireframes) of the Voxe platform.
8
9

10 Following the task-based activities, healthcare provider participants will complete the
11
12 System Usability Scale, a 10 item Likert scale questionnaire to assess the key performance
13
14 indicator satisfaction.(30, 31) The System Usability Scale is considered a reliable way to
15
16 evaluate electronic platforms and a score of 68 is considered above average.(30, 31) Patient
17
18 participant's overall impression and experience with the Voxe platform will be evaluated using
19
20 the Microsoft Desirability Toolkit.(32) Patient participants will select five words from a list of
21
22 product reaction words to describe their attitude towards the Voxe platform. Product reaction
23
24 words, such as "fun" and "calm" describe intangible emotional response towards the
25
26 interface.(33)
27
28
29
30
31

32 Lastly, participants will share their likes and dislikes of the Voxe platform design and
33
34 comment on the platform's ease of use and elements of functionality during a virtual semi-
35
36 structured qualitative interview. Semi-structured interviews foster reciprocity between the
37
38 participant and interviewer, allow the interviewer to ask pertinent follow-up questions to elicit
39
40 rich data and enable the participant to express themselves using their own words.(34-36) The
41
42 interview guide will be developed by the study team and will be informed by clinical knowledge
43
44 and experience. Interviews will be conducted by study team members trained in qualitative
45
46 methods. Sessions will be audio-recorded, transcribed verbatim and de-identified to protect
47
48 participant confidentiality. Recruitment for Phase 4 began in May 2020.
49
50
51
52
53

54 Data analysis

55
56
57
58
59
60

1
2
3 Data collected during the testing sessions, including objective and subjective
4
5 International Organization for Standardization key performance indicators, will be used to
6
7 refine Voxe. The research team will utilize content and thematic analysis to categorize the data
8
9 collected during qualitative interviews.(37-39) Two members of the study team experienced in
10
11 qualitative methods, will code the data independently, and categories will be reviewed and
12
13 refined until consensus is reached for emerging themes. Trustworthiness will be achieved by
14
15 facilitating member checking and soliciting rich description during interviews, as well as hosting
16
17 frequent team meetings to support in-depth, iterative analysis with reflexive discussion among
18
19 team members. Analysis will be complete once the research team agrees that thematic
20
21 saturation is attained.(39) NVivo 12 will be used to manage qualitative data.(40) Quantitative
22
23 data collected during the testing sessions will be triangulated with qualitative themes to
24
25 provide a richer understanding of end-users' experience with Voxe. Refinements will be made
26
27 to the Voxe platform design based on the triangulated data. Three rounds of iterative feedback
28
29 testing will be conducted with each participant population (i.e. four participants per round)
30
31 until Voxe is considered acceptable to participating end-users with no further refinements
32
33 identified.(41, 42) Following the third round of patient and healthcare provider iterative testing,
34
35 the design team will share the final Voxe patient and healthcare provider annotated wireframes
36
37 with the development team.

Phase 5: Development of ePROM platform Voxe and usability testing

46
47
48 Usability is defined as the “extent to which a system, product or service can be used by
49
50 specified users to achieve specified goals with effectiveness, efficiency and satisfaction in a
51
52 specified context of use”.(24) To test Voxe usability, the think-aloud technique will be
53
54
55
56
57
58
59
60

1
2
3 employed in which participants will verbalize their thoughts and feelings while interacting with
4
5 Voxe to complete structured tasks.(43, 44) The think-aloud technique is integral to
6
7 understanding the end-user experience with Voxe and will highlight potential barriers to Voxe
8
9 adoption that can inform its subsequent implementation.(43, 44) Semi-structured interviews
10
11 and data analytics, described below, will also be conducted.(45)
12
13
14

15 Study participants and inclusion criteria

16
17
18 Purposive sampling will be used to recruit 12 to 20 patient participants across age,
19
20 organ type, sex, gender, and ethnicity from the Transplant and Regenerative Medicine Centre
21
22 at SickKids. Twelve to 20 members of the patients' interdisciplinary healthcare team will also be
23
24 recruited purposively across professional disciplines, years of practice, sex, gender and
25
26 ethnicity.(23)
27
28
29

30 Patients eligible to participate will include those who are: (a) eight to 17 years of age
31
32 with capacity to assent/consent, (b) those able to speak and read English, (c) heart, kidney, liver
33
34 or lung transplant recipients, and (d) who are a minimum of three months post-transplant.
35
36 Informed consent will be obtained from the parents/legal guardians of participants who
37
38 provide assent. Eligible healthcare providers include any member of the interdisciplinary
39
40 healthcare team within the Transplant and Regenerative Medicine Centre at SickKids who have
41
42 worked within their position for a minimum of six months.
43
44
45

46 Procedures and outcomes

47
48
49 Following Phase 4, the development team will use the Voxe patient and healthcare
50
51 provider annotated wireframes to develop the respective interfaces of the Voxe ePROM
52
53 platform, using an agile, scrum framework.(19) A scrum framework is a project management
54
55
56
57
58
59
60

1
2
3 process within a hybrid software development model that applies a flexible development
4
5 process and places the needs of system end-users at the forefront to ensure that Voxe is both
6
7 useful and usable.(46, 47) The principles of iterative feedback, incremental development and
8
9 continual stakeholder involvement are central to this dynamic approach.(46, 47) Feature
10
11 development will be phased and will include authentication, user dashboards, account settings,
12
13 privacy/security controls and survey submission/review functionality.
14
15
16

17
18 Four rounds of iterative testing will be completed with three to five patients and three
19
20 to five healthcare providers per round, as is consistent with usability testing methods for clinical
21
22 information systems.(23) The first two rounds will be conducted in-person or virtual with a
23
24 member of the study team, using smartphones, tablets and/or computers. Both patient and
25
26 healthcare provider participants will be asked to complete a core set of tasks on Voxe which will
27
28 be presented to them in the form of scenarios that they may encounter while interacting with
29
30 Voxe. For example, patients will be provided with an anonymous username and password,
31
32 invited to successfully log into Voxe, and navigate Voxe to complete available ePROMs (i.e.
33
34 PedsQL™ Generic Core Scales(48)). Healthcare providers will be invited to navigate Voxe to
35
36 view and interpret sample ePROM results. Employing think-aloud methodology, participants
37
38 will be encouraged to voice out loud what they are looking at, thinking, doing and feeling as
39
40 they navigate the platform.(43, 45)
41
42
43
44
45
46

47 The last two testing rounds will be conducted to simulate 'real-world' settings.
48
49 An automated text message or email with an embedded hyperlink will be sent to patients
50
51 asking them to access Voxe remotely on a smartphone, tablet or computer. Patients will
52
53 independently log into Voxe using an anonymous username and password and navigate the
54
55
56
57
58
59
60

1
2
3 platform to complete available ePROMs. Healthcare providers will be asked to access Voxe on a
4
5 computer and independently navigate the Voxe platform to view and interpret ePROM data
6
7 entered by patients.
8
9

10 Objective measures to be collected include: (1) time on task – the time it takes to
11
12 complete each task, (2) successful task completion (fidelity) – when the end-user achieves the
13
14 end goal of the task successfully (above the average task completion rate of 78% is considered
15
16 successful(27, 28)), (3) frequency of critical errors – a high severity error that could prevent an
17
18 end-user from being able to complete a task, (4) frequency of non-critical errors – a low
19
20 severity error that could decrease the efficiency with which an end-user completes a task, and
21
22 (5) error-free rate – the percentage of task completions that occurred without any errors.(49,
23
24 50) After the completion of task based activities, participant satisfaction will be evaluated.
25
26 Healthcare provider participants will complete the System Usability Scale. A score on the
27
28 System Usability Scale that is greater than 68 is considered above average.(30, 31) Patient
29
30 participants will complete the Microsoft Desirability Toolkit by selecting words from a list of
31
32 product reaction words to describe their attitude towards the Voxe platform.(32, 33) Following
33
34 each testing round, in-person or virtual semi-structured interviews will be conducted to
35
36 ascertain what participants liked or disliked and why, ease of use, elements of functionality in
37
38 the context of typical practice workflow, as well as suggestions for improvements. Iterative
39
40 usability testing will also be conducted until Voxe is considered acceptable to participating end-
41
42 users with no further refinements identified.(41, 42) Interviews will be audio-recorded,
43
44 transcribed verbatim and de-identified.
45
46
47
48
49
50
51
52
53

54 Data analysis

55
56
57
58
59
60

1
2
3 Quantitative data including time on task, successful task completion, frequency of
4
5 critical and non-critical errors, and error-free rate will be analyzed and descriptive statistics will
6
7 be produced. Similar to Phase 4, qualitative interviews will be subject to content and thematic
8
9 analysis to identify emerging themes.(37, 38) Themes will be coded and categorized using
10
11 NVivo 12 according to type and frequency of occurrence.(40) Quantitative and qualitative data
12
13 will be triangulated to inform changes made to the Voxe platform.
14
15
16

Patient and public involvement

17
18
19 Phases 4 and 5 are informed by the invaluable feedback provided by stakeholders,
20
21 including pediatric patients, their caregivers and healthcare providers, from previous phases of
22
23 research.(16) Patients' and healthcare providers' thoughts, feelings and perspectives about
24
25 Voxe captured through research processes described in this protocol will continue to guide this
26
27 research program. Stakeholder involvement will ensure the implementation of evidence-based
28
29 interventions integral to achieving meaningful patient outcomes.
30
31
32
33

ETHICS AND DISSEMINATION

Ethics approval and consent to participate

34
35
36
37
38 Institutional research ethics board approval has been provided by SickKids (REB number:
39
40 1000057043 (Phase 4); REB number: 1000067700 (Phase 5)). All participants will provide
41
42 informed consent or assent prior to their involvement in the study. For participants who
43
44 provide informed assent, informed consent will be obtained from the parents/legal guardians
45
46 prior to study participation.
47
48
49
50

Information security

1
2
3 All interviews will be audio recorded and transcribed verbatim. Transcription will be completed
4
5 by a member of the study team. All transcriptions will be de-identified to protect participant
6
7 confidentiality. All identifying information, both paper copy and electronic information, will be
8
9 kept confidential. Use of data over the course of the study and dissemination of results will
10
11 follow standard practice guidelines as determined by the SickKids Research Institute.
12
13

14 **Discussion and dissemination**

15
16 The collection of PROMs provides the opportunity to incorporate patient-centred
17
18 perspectives into pediatric clinical practice.(2, 6, 11, 51-54) The creation of the Voxe ePROM
19
20 platform will reform the practice of pediatric medicine by enhancing the capacity of patient-
21
22 provider partnerships to identify and address issues that are most meaningful to patients.(55)
23
24 The design and development of Voxe outlined in this protocol are critical to answering
25
26 important methodological and operational questions that will inform the implementation of
27
28 ePROMs in pediatric clinical settings.
29
30
31
32
33

34
35 Engaging patients and healthcare providers throughout Voxe design and development
36
37 will result in the creation and launch of a user-centred ePROM platform. For patients, Voxe will
38
39 facilitate ePROM data collection in a child friendly and patient-centred manner. For healthcare
40
41 providers, Voxe will facilitate convenient and timely review of patient ePROM data,
42
43 collaboration within healthcare teams, and shared decision-making discussions between
44
45 healthcare providers and patients during clinical encounters.
46
47
48

49
50 During Phase 4, patients and healthcare providers will share their likes and dislikes of
51
52 the design and comment on Voxe functionality and ease of use. It is critical that Voxe design
53
54 iterations integrate this feedback, as the interface needs to be designed in a way that is logical,
55
56
57
58
59
60

1
2
3 intuitive, and user friendly for end-users. This process will ensure that there is an evidence-
4
5 based iterative design in place before usability testing. In Phase 5, patients and healthcare
6
7 providers will comment on what they liked or disliked about Voxe and why, Voxe ease of use,
8
9 and elements of functionality in the context of typical practice workflow, as well as suggestions
10
11 to improve Voxe. Voxe will be further refined according to this feedback until a final version is
12
13 produced. The final product will enhance the experience of end-users with systematically
14
15 tested functionality and design. Following the procedures outlined above, creating an evidence-
16
17 based ePROM platform will enable these outcomes. Findings from this study will be widely
18
19 disseminated through infographics, posts on the research team's website, peer-reviewed
20
21 journal publications and presentations at patient and family educational events as well as
22
23 scientific and academic conferences. Data collection is expected to be completed by the end of
24
25 2021 with publication of results in early 2022.
26
27
28
29
30
31

32 This research lays the groundwork for future investigations that will include Voxe
33
34 healthcare provider orientation and competency training as part of a more comprehensive
35
36 implementation plan. Additionally, an implementation-effectiveness evaluation (Phase 6) of the
37
38 Voxe ePROM platform will be conducted to explore how Voxe can be effectively implemented
39
40 in a manner that impacts pediatric transplantation patient's health outcomes and clinical care.
41
42
43
44

45 **List of abbreviations**

46 ePROM – Electronic patient-reported outcome measure

47 PROM – Patient-reported outcome measure
48

49 ***Figure Caption***

50 Figure 1: Measuring What Matters: Implementing Patient-Reported Outcome Measures into
51
52 Clinical Practice – A Research Program
53

54 ***Acknowledgements***

55 The authors thank our patient partners and past and future research participants.
56
57
58
59
60

Competing interests

The authors declare that they have no competing interests.

Funding

This study was supported by the SickKids Transplant and Regenerative Medicine Centre and Astellas Pilot Grant (Grant/Award Number: Not Applicable), the Canadian Donation and Transplantation Research Program Innovation Grant (Grant/Award Number: Not Applicable) and the Health Canada Health Care Policy Contribution Program (Grant/Award Number: 1920-HQ-000105).

Authors' contributions

All authors (SJA, SJP, JL, MBa, MBr, DM, RSP, AS, JS) contributed to project conception and study design. SJA, SJP and JL drafted the manuscript. All authors (SJA, SJP, JL, MBa, MBr, DM, RSP, AS, JS) read the manuscript and gave final approval of the version to be published.

References

1. Rossano JW, Cherikh WS, Chambers DC, Goldfarb S, Hayes D, Khush KK, et al. The international thoracic organ transplant registry of the International Society for Heart and Lung Transplantation: Twenty-first pediatric heart transplantation report—2018; Focus theme: Multiorgan transplantation. *J Heart Lung Transplant*. 2018;37(10):1184-95.
2. Bevans KB, Moon J, Carle AC, Mara CA, Lai J-S, DiMarco L, et al. Patient reported outcomes as indicators of pediatric health care quality. *Acad Pediatr*. 2014;14(5):S90-S6.
3. US Department of Health Human Services Food and Drug Administration. Guidance for industry - Patient-reported outcome measures: Use in medical product development to support labeling claims. *Fed Reg*. 2009;74(235):65132–3.
4. Santana M-J, Feeny D. Framework to assess the effects of using patient-reported outcome measures in chronic care management. *Qual Life Res*. 2014;23(5):1505-13.
5. Fung CH, Hays RD. Prospects and challenges in using patient-reported outcomes in clinical practice. *Qual Life Res*. 2008;17(10):1297-302.
6. Bitton A, Onega T, Tosteson AN, Haas JS. Toward a better understanding of patient-reported outcomes in clinical practice. *Am J Manag Care*. 2014;20(4):281.
7. Nelson EC, Eftimovska E, Lind C, Hager A, Wasson JH, Lindblad S. Patient reported outcome measures in practice. *BMJ*. 2015;350.
8. Valderas J, Kotzeva A, Espallargues M, Guyatt G, Ferrans C, Halyard M, et al. The impact of measuring patient-reported outcomes in clinical practice: A systematic review of the literature. *Qual Life Res*. 2008;17(2):179-93.
9. Forrest CB. Digitization of patient-reported outcomes. *Value Health*. 2013;16(4):459-60.
10. McCurdie T, Taneva S, Casselman M, Yeung M, McDaniel C, Ho W, et al. mHealth consumer apps: The case for user-centered design. *Biomed Instrum Technol*. 2012;46(Suppl 2):49-56.
11. Huang I-C, Revicki DA, Schwartz CE. *Measuring pediatric patient-reported outcomes: Good progress but a long way to go*. Springer; 2014.
12. Hoffmann T, Bennett S, Del Mar C. *Evidence-based practice across the health professions-e-book*: Elsevier Health Sciences; 2013.
13. Aaronson N, Elliott T, Greenhalgh J, Halyard M, Hess R, Miller D, et al. *User's guide to implementing patient-reported outcomes assessment in clinical practice version 2*. 2015.
14. Anthony SJ, Stinson H, Lazor T, Young K, Hundert A, Santana MJ, et al. Patient-reported outcome measures within pediatric solid organ transplantation: A systematic review. *Pediatr Transplant*. 2019;23(6):e13518.
15. Terwee CB, Mokkink LB, Knol DL, Ostelo RW, Bouter LM, de Vet HC. Rating the methodological quality in systematic reviews of studies on measurement properties: A scoring system for the COSMIN checklist. *Qual Life Res*. 2012;21(4):651-7.
16. Anthony SJ, Young K, Pol SJ, Selkirk EK, Blydt-Hansen T, Boucher S, et al. Patient-reported outcome measures in pediatric solid organ transplantation: Exploring stakeholder perspectives on clinical implementation through qualitative description. *Qual Life Res*. 2021.
17. Meyers DC, Durlak JA, Wandersman A. The quality implementation framework: A synthesis of critical steps in the implementation process. *Am J Community Psychol*. 2012;50(3-4):462-80.

18. Verhoeven F, Tanja-Dijkstra K, Nijland N, Eysenbach G, van Gemert-Pijnen L. Asynchronous and synchronous teleconsultation for diabetes care: A systematic literature review. *J Diabetes Sci Technol*. 2010;4(3):666-84.
19. Barnum CM. Chapter 1: Establishing the essentials. In: Merken S, editor. *Usability testing essentials: ready, set test!* 2 ed. Amsterdam: Elsevier; 2020. p. 9-33.
20. US General Services Administration Technology Transformation Services. *Wireframing 2021* [Available from: <https://www.usability.gov/how-to-and-tools/methods/wireframing.html>].
21. ProductPlan. *Wireframe 2021* [Available from: <https://www.productplan.com/glossary/wireframe/>].
22. Palinkas LA, Horwitz SM, Green CA, Wisdom JP, Duan N, Hoagwood K. Purposeful sampling for qualitative data collection and analysis in mixed method implementation research. *Adm Policy Ment Health*. 2015;42(5):533-44.
23. Kushniruk AW, Patel VL. Cognitive and usability engineering methods for the evaluation of clinical information systems. *J Biomed Inform*. 2004;37(1):56-76.
24. International Organization for Standardization. *ISO 9241-11:2018(en) Ergonomics of human-system interaction — Part 11: Usability: Definitions and concepts 2018* [Available from: <https://www.iso.org/obp/ui/#iso:std:iso:9241:-11:ed-2:v1:en>].
25. International Organization for Standardization. *About us: What we do* [Available from: <https://www.iso.org/what-we-do.html>].
26. Barnum CM. Chapter 8: Analyzing the findings. In: Merken S, editor. *Usability testing essentials: ready, set test!* 2 ed. Amsterdam: Elsevier; 2020. p. 287-319.
27. Sauro J. *What Is A Good Task-Completion Rate? Secondary What Is A Good Task-Completion Rate?* 2011 [Available from: <https://measuringu.com/task-completion/>].
28. Cho H, Powell D, Pichon A, Kuhns LM, Garofalo R, Schnall R. Eye-tracking retrospective think-aloud as a novel approach for a usability evaluation. *International journal of medical informatics*. 2019;129:366-73.
29. International Organization for Standardization. *ISO 9000:2015(en) Quality management systems — Fundamentals and vocabulary 2015* [Available from: <https://www.iso.org/obp/ui/#iso:std:iso:9000:ed-4:v1:en>].
30. Haggerty T, Brabson L, Grogg KA, Herschell AD, Giacobbi Jr P, Sedney C, et al. Usability testing of an electronic health application for patient activation on weight management. *Mhealth*. 2021;7.
31. Brooke J. SUS-A quick and dirty usability scale. *Usability evaluation in industry*. 1996;189(194):4-7.
32. Barnum C. Chapter 6: Preparing for usability testing. In: Merken S, editor. *Usability testing essentials: ready, set test!* 2 ed. Amsterdam: Elsevier; 2020. p. 197-248.
33. Benedek J, Miner T. Measuring desirability: New methods for evaluating desirability in a usability lab setting. *Usability Professionals Association*. 2002;2003(8-12):57.
34. Galletta A. *Mastering the semi-structured interview and beyond: From research design to analysis and publication*: NYU Press; 2013.
35. Rubin HJ, Rubin IS. *Qualitative interviewing: The art of hearing the data*. 2 ed. Thousand Oaks, CA: SAGE; 2005.

- 1
- 2
- 3
- 4 36. Kallio H, Pietilä AM, Johnson M, Kangasniemi M. Systematic methodological review: Developing a framework for a qualitative semi-structured interview guide. *J Adv Nurs*. 2016;72(12):2954-65.
- 5
- 6
- 7 37. Gibbs G. *Analysing qualitative data*. London, England: SAGE; 2007.
- 8 38. Fereday J, Muir-Cochrane E. Demonstrating rigor using thematic analysis: A hybrid approach of inductive and deductive coding and theme development. *Int J Qual Methods*. 2006;5(1):80-92.
- 9
- 10 39. Elo S, Kyngäs H. The qualitative content analysis process. *J Adv Nurs*. 2008;62(1):107-15.
- 11 40. Richards L. *Using NVivo in qualitative research*: Sage; 1999.
- 12 41. Stinson JN, Jibb LA, Nguyen C, Nathan PC, Maloney AM, Dupuis LL, et al. Development and testing of a multidimensional iPhone pain assessment application for adolescents with cancer. *J Med Internet Res*. 2013;15(3):e51.
- 13 42. Macefield R. How to specify the participant group size for usability studies: A practitioner's guide. *J Usability Stud*. 2009;5(1):34-45.
- 14 43. Li AC, Kannry JL, Kushniruk A, Chrimes D, McGinn TG, Edonyabo D, et al. Integrating usability testing and think-aloud protocol analysis with "near-live" clinical simulations in evaluating clinical decision support. *Int J Med Inform*. 2012;81(11):761-72.
- 15 44. Rose AF, Schnipper JL, Park ER, Poon EG, Li Q, Middleton B. Using qualitative studies to improve the usability of an EMR. *J Biomed Inform*. 2005;38(1):51-60.
- 16 45. Lewis C. *Using the "think aloud" method in cognitive interface design*. New York: IBM. 1982.
- 17 46. Cervone F. Understanding agile project management methods using scrum. *OCLC Systems & Services International digital library perspectives*. 2011;1(27):18-22.
- 18 47. Brhel AM, H; Maedche, A; Werder, K. Exploring principles of user-centred agile software development: A literature review. *Information and Software Technology*. 2015(61):163-81.
- 19 48. Varni J, Seid M, Kurtin P. PedsQL TM 4.0: Reliability and validity of the Pediatric Quality of Life Inventory TM Version 4.0 Generic Core Scales in healthy and patient populations. *Med Care*. 2001;39:800-12.
- 20 49. US General Services Administration Technology Transformation Services. Planning a Usability Test 2021 [Available from: <https://www.usability.gov/how-to-and-tools/methods/planning-usability-testing.html>].
- 21 50. Tullis TA, Bill. Chapter 4 – Performance Metrics. *Measuring the User Experience*. Second ed: Elsevier; 2013. p. 63–97.
- 22 51. Calvert M, Kyte D, Price G, Valderas JM, Hjollund NH. Maximising the impact of patient reported outcome assessment for patients and society. *BMJ*. 2019;364.
- 23 52. Haverman L, Engelen V, van Rossum MA, Heymans HS, Grootenhuis MA. Monitoring health-related quality of life in paediatric practice: Development of an innovative web-based application. *BMC Pediatr*. 2011;11(1):1-7.
- 24 53. Haywood K, Brett J, Salek S, Marlett N, Penman C, Shklarov S, et al. Patient and public engagement in health-related quality of life and patient-reported outcomes research: What is important and why should we care? Findings from the first ISOQOL patient engagement symposium. *Qual Life Res*. 2015;24(5):1069-76.
- 25 54. Cleemput I, Dobbels F. Measuring patient-reported outcomes in solid organ transplant recipients. *Pharmacoeconomics*. 2007;25(4):269-86.
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1
2
3 55. Engelen V, Detmar S, Koopman H, Maurice-Stam H, Caron H, Hoogerbrugge P, et al.
4 Reporting health-related quality of life scores to physicians during routine follow-up visits of
5 pediatric oncology patients: Is it effective? *Pediatr Blood Cancer*. 2012;58(5):766-74.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Figure 1: Measuring What Matters: Implementing Patient-Reported Outcome Measures into Clinical Practice – A Research Program

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47



For peer review only

GUIDED – a guideline for reporting for intervention development studies.

Supplementary File 1: Blank Checklist

Item description	Explanation	Page in manuscript where item is located	Other*
1. Report the context for which the intervention was developed.	Understanding the context in which an intervention was developed informs readers about the suitability and transferability of the intervention to the context in which they are considering evaluating, adapting or using the intervention. Context here can include place, organisational and wider socio-political factors that may influence the development and/or delivery of the intervention (15).	9, 10, 13, 14	
2. Report the purpose of the intervention development process.	Clearly describing the purpose of the intervention specifies what it sets out to achieve. The purpose may be informed by research priorities, for example those identified in systematic reviews, evidence gaps set out in practice guidance such as The National Institute for Health and Care Excellence or specific prioritisation exercises such as those undertaken with patients and practitioners through the James Lind Alliance.	8	
3. Report the target population for the intervention development process.	The target population is the population that will potentially benefit from the intervention – this may include patients, clinicians, and/or members of the public. If the target population is clearly described then readers will be able to understand the relevance of the intervention to their own research or practice. Health inequalities, gender and ethnicity are features of the target population that may be relevant to intervention development processes.	9, 10, 13, 14	
4. Report how any published intervention development approach contributed to the development process	Many formal intervention development approaches exist and are used to guide the intervention development process (e.g. 6Squid (16) or The Person Based Approach to Intervention Development (17)). Where a formal intervention development approach is used, it is helpful to describe the process that was followed, including any deviations. More general approaches to intervention development also exist and have been categorised as follows (3):- Target Population-centred intervention development; evidence and theory-based intervention development; partnership intervention development; implementation-based intervention development; efficacy-based intervention development; step or phased-based intervention development; and intervention-specific intervention development (3). These approaches do not always have specific guidance that describe their use. Nevertheless, it is helpful to give a rich description of how any published approach was operationalised	9, 13, 14	
5. Report how evidence from different sources informed the intervention development process.	Intervention development is often based on published evidence and/or primary data that has been collected to inform the intervention development process. It is useful to describe and reference all forms of evidence and data that have informed the development of the intervention because evidence bases can change rapidly, and to explain the manner in which the evidence and/or data was used. Understanding what evidence was and was not available at the time of intervention development can help readers to assess transferability to their current situation.	6-8	
6. Report how/if published theory informed the intervention development process.	Reporting whether and how theory informed the intervention development process aids the reader's understanding of the theoretical rationale that underpins the intervention. Though not mentioned in the e-Delphi or consensus meeting, it became increasingly apparent through the development of our guidance that this theory item could relate to either existing published theory or programme theory	5, 6, 9, 13, 14	
7. Report any use of components from an existing intervention in the current intervention development process.	Some interventions are developed with components that have been adopted from existing interventions. Clearly identifying components that have been adopted or adapted and acknowledging their original source helps the reader to understand and distinguish between the novel and adopted components of the new intervention.	5, 6	
8. Report any guiding principles, people or factors that were prioritised when making decisions during the intervention development process.	Reporting any guiding principles that governed the development of the application helps the reader to understand the authors' reasoning behind the decisions that were made. These could include the examples of particular populations who views are being considered when designing the intervention, the modality that is viewed as being most appropriate, design features considered important for the target population, or the potential for the intervention to be scaled up.	5-8	

Item description	Explanation	Page in manuscript where item is located	Other*
9. Report how stakeholders contributed to the intervention development process.	Potential stakeholders can include patient and community representatives, local and national policy makers, health care providers and those paying for or commissioning health care. Each of these groups may influence the intervention development process in different ways. Specifying how differing groups of stakeholders contributed to the intervention development process helps the reader to understand how stakeholders were involved and the degree of influence they had on the overall process. Further detail on how to integrate stakeholder contributions within intervention reporting are available (19).	6-11, 13-15	
10. Report how the intervention changed in content and format from the start of the intervention development process.	Intervention development is frequently an iterative process. The conclusion of the initial phase of intervention development does not necessarily mean that all uncertainties have been addressed. It is helpful to list remaining uncertainties such as the intervention intensity, mode of delivery, materials, procedures, or type of location that the intervention is most suitable for. This can guide other researchers to potential future areas of research and practitioners about uncertainties relevant to their healthcare context.	N/A	
11. Report any changes to interventions required or likely to be required for subgroups.	Specifying any changes that the intervention development team perceive are required for the intervention to be delivered or tailored to specific sub groups enables readers to understand the applicability of the intervention to their target population or context. These changes could include changes to personnel delivering the intervention, to the content of the intervention, or to the mode of delivery of the intervention.	N/A	
12. Report important uncertainties at the end of the intervention development process.	Intervention development is frequently an iterative process. The conclusion of the initial phase of intervention development does not necessarily mean that all uncertainties have been addressed. It is helpful to list remaining uncertainties such as the intervention intensity, mode of delivery, materials, procedures, or type of location that the intervention is most suitable for. This can guide other researchers to potential future areas of research and practitioners about uncertainties relevant to their healthcare context.	N/A	
13. Follow TIDieR guidance when describing the developed intervention.	Interventions have been poorly reported for a number of years. In response to this, internationally recognized guidance has been published to support the high quality reporting of health care? interventions ⁵ and public health interventions ¹⁴ . This guidance should therefore be followed when describing a developed intervention.	N/A	
14. Report the intervention development process in an open access format.	Unless reports of intervention development are available people considering using an intervention cannot understand the process that was undertaken and make a judgement about its appropriateness to their context. It also limits cumulative learning about intervention development methodology and observed consequences at later evaluation, translation and implementation stages. Reporting intervention development in an open access (Gold or Green) publishing format increases the accessibility and visibility of intervention development research and makes it more likely to be read and used. Potential platforms for open access publication of intervention development include open access journal publications, freely accessible funder reports or a study web-page that details the intervention development process.	N/A	

*e.g. if item is reported elsewhere, then the location of this information can be stated here.